Macrocyclic compound and method for producing same
Macrocyclic compounds enable site-specific conjugation with targeting ligands, addressing the stability and efficacy issues of existing chelating agents for actinium-225, resulting in improved radioimmunoconjugates for targeted tumor therapy.
Patent Information
- Application Number
- JP2024527162
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-06
- Filing Date
- 2022-11-08
- Publication Date
- 2024-11-13
AI Technical Summary
Current chelating agents for actinium-225, such as DOTA, face challenges in achieving stable and efficient binding with high specificity, requiring harsh conditions or high agent-to-radioisotope ratios, which affects the efficacy and safety of radioimmunoconjugates.
Development of macrocyclic compounds capable of site-specific conjugation with targeting ligands like antibodies using 'click chemistry', forming stable radioimmunoconjugates with high specific activity and yield, utilizing actinium-225 and other alpha-emitting radiometals.
The new macrocyclic compounds provide stable and efficient radioimmunoconjugates with improved targeting specificity and reduced toxicity, enhancing the effectiveness of targeted radiotherapy for tumor cells.
Smart Images

Figure 2024542168000184 
Figure 2024542168000185 
Figure 2024542168000186
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 277,278, filed November 9, 2021, and U.S. Provisional Patent Application No. 63 / 338,949, filed May 6, 2022, which are incorporated by reference herein in their entireties for all purposes.
[0002] (Reference to electronically submitted sequence listing) This application contains a computer readable sequence listing that has been submitted herewith in XML file format, the entire contents of which are incorporated herein by reference in their entirety. The sequence listing XML file submitted herewith is entitled "JBI6638WOPCT1_SL.xml", was created on November 2, 2022, and is 27,422 bytes in size.
[0003] FIELD OF THEINVENTION The present invention is directed to the preparation of key intermediates and to the synthesis of macrocycles and their pharma- ceutical acceptable salts, as well as immunoconjugates and radioimmunoconjugates containing same. [Background technology]
[0004] Alpha particle emitting radionuclides are very promising for cancer therapy due to the combination of high linear energy deposition and short-range action, offering the potential for potent killing that is mostly localized to tumor cells (Kim, Y Sand MW Brechbiel, An overview of targeted alpha therapy. Tumour Biol, 2012. 33(3): p. 573-90). Targeted delivery of alpha emitters using antibodies, scaffold proteins, small molecule ligands, aptamers, or other binding moieties specific for cancer antigens provides a method for selective delivery of radionuclides to tumors, enhancing their efficacy and reducing off-target effects. In common practice, the binding moiety is attached to a chelator that binds to an alpha emitting radiometal to generate a radiocomplex. Many such examples use monoclonal antibodies (mAbs) as targeting vectors to generate what are known as radioimmunoconjugates.
[0005] Actinium 225( 225 Actinium-225 (Ac) is an alpha-emitting radioisotope of particular interest for medical applications (Miederer et al., Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev, 2008. 60(12):71-82). 225 The half-life of Ac is 10 days, which is long enough to facilitate the generation of radioconjugates, but short enough to match the circulating pharmacokinetics of a delivery vehicle such as an antibody. 225 Of particular interest are Ac radioconjugates. 225 Ac is a stable isotope 209 By the time we reach Bi, 225It decays in a series of steps emitting a total of four alpha particles per Ac decay, thus increasing its potency. Another radioisotope of interest for medical applications is lutetium-177, which emits both gamma radiation suitable for imaging and medium-energy beta radiation suitable for radiotherapy. 177 Lu). 177 Lu-labeled peptides demonstrated reduced normal tissue damage, 177 Lu labeling has been shown to enable the use of a single radioactive labeling agent for both therapy and imaging (Kwekkeboom DJ, et al. 177 Lu-DOTA 0 ,Tyr 3 ]octreotate:comparison with[ 111 In-DTPA 0 ]octreotide in patients. Eur J Nucl Med. 2001;28:p.1319-1325). Other radioisotopes used for therapeutic applications include, for example, beta-emitters or alpha-emitters, e.g. 32 P, 47 Sc, 67 Cu, 77 As, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 131 I, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 255 Fm and 227Other radioisotopes used in imaging applications include, for example, 62 Cu, 64 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, and 111 and gamma-ray and / or positron-emitting radioisotopes such as In.
[0006] Currently, the most widely used chelator for actinium-225 and lanthanides is DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; tetraxathen), and previous clinical and preclinical programs have primarily used 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for actinium chelation. However, it is known that DOTA chelation of actinium can be difficult (Deal, KA, et al., Improved in vivo stability of actinium-225 macrocyclic complexes. J Med Chem, 1999.42(15):p.2988-92). For example, DOTA, when conjugated to a targeting ligand such as a protein or antibody, only allows a maximum chelation ratio of >500:1 DOTA:actinium-225, often requiring either harsh conditions or high levels of DOTA per antibody. Other macrocyclic chelators for lanthanides and actinium-225 are described, for example, in WO 2018 / 183906; Thiele et al., "An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy," Angew. Chem. Int. Ed. (2017) 56, 14712-14717; Roca-Sabio et al., "Macrocyclic Receptor Exhibiting Unprecedented Selectivity for Light Lanthanides," J. Am. Chem. Soc. (2009) 131, 3331-3341.
[0007] Site specificity has become a major area of focus in the antibody-drug conjugate (ADC) field, as it has been demonstrated that site-specific approaches can enhance both the efficacy and safety of ADCs compared to random conjugation (Agarwal, P. and C.R. Bertozzi, Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development, Bioconjug Chem, 2015.26(2):p.176-92). It is believed that similar safety and efficacy benefits may be achieved with radioimmunoconjugates. Summary of the Invention
[0008] Described herein are processes for making key intermediates for use in the preparation of the compounds, immunoconjugates, and radioimmunoconjugates of the invention.
[0009] The novel compounds of the present invention are capable of reacting with radioactive metals, preferably actinium 225 ( 225 The present invention can be used to bind alpha-emitting radiometals, such as alpha-emitting radiometals, e.g., Ac), and generate stable radioimmunoconjugates with high specific activity and high yields. The present invention provides a method for the preparation of radioactive metals, e.g., alpha-emitting radiometal ... 225 Ac and imaging radiometals, e.g. 134The present invention provides macrocyclic compounds capable of chelating Ce. The compounds of the present invention can be used to generate radioimmunoconjugates with high stability in vitro and in vivo by conjugating the compounds of the present invention to targeting ligands, such as antibodies, proteins, aptamers, etc., preferably in a site-specific manner using "click chemistry". The radioimmunoconjugates generated by conjugating the compounds of the present invention to targeting ligands can be used for targeted radiotherapy, such as targeted radiotherapy of tumor cells, and / or targeted treatment of tumor diseases or disorders, including cancer.
[0010] One embodiment of the present invention provides a process for preparing compound 14.
[0011] [ka]
[0012] One embodiment of the present invention provides intermediates in the preparation of the compounds described below that are capable of chelating with a radiometal.
[0013] In one embodiment of the present invention, compound 14
[0014] [ka] A generalized synthetic process for preparing N-(2-(2-methyl-1,2-dioxane)-1,2-diol or a pharma- ceutically acceptable salt or solvate thereof comprises the steps of:
[0015] [ka] reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof at a temperature ranging from ambient temperature to about −78° C. to obtain compound 2;
[0016] [ka] reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 3;
[0017] [ka] reacting 3 with 2 in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate);
[0018] [ka] reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 in an organic solvent or mixture thereof under reducing conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 7;
[0019] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate);
[0020] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 9;
[0021] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10;
[0022] [ka] reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain 13, which is reacted with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14.
[0023] In a further embodiment of compound 14, compound 10
[0024] [ka] A generalized synthetic process for preparing N-(2-(2-methyl-1,2-dioxane)-1,2-diol or a pharma- ceutically acceptable salt or solvate thereof comprises the steps of:
[0025] [ka] The method includes the steps of reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or a mixture thereof at a temperature ranging from about ambient temperature to about −78° C., stirring for 5 to 60 minutes, and reacting the resultant with trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent or a mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 10.
[0026] Removal of the t-butoxycarbonyl protecting group proved difficult and many conditions were tried without success. Attempts were made under acidic and basic conditions (HCl, TFA, MSA, phosphoric acid, KOAc / AcOH, TsCl-DMAP, BF3, OEt2, TMSCl, and CsCO3), all of which led to rapid decomposition of compound 9.
[0027] The conditions for successful deprotection using BSA and TMSOTf reagents were unexpected and novel.
[0028] In one aspect of the present invention, the intermediate is represented by formula (14): Free Base Compounds
[0029] [ka] or a pharma- ceutically acceptable salt or solvate thereof.
[0030] Another embodiment of the present invention is a compound of formula (11)
[0031] [ka] or a pharma- ceutically acceptable salt or solvate thereof.
[0032] Another aspect of the present invention is intermediate compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt).
[0033] [ka] or a pharma- ceutically acceptable salt or solvate thereof.
[0034] One embodiment of the present invention is compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt).
[0035] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0036] [ka] reacting compound 10 with sodium hydroxide in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 11;
[0037] [ka] reacting compound 11 with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 12.
[0038] Additionally, the present invention includes compounds capable of forming complexes with the radiometals, radiometal complexes, and radioimmunoconjugates described herein.
[0039] One embodiment of the present invention relates to a compound of formula (I):
[0040] [ka] or a pharma- ceutically acceptable salt thereof, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, the 5- or 6-membered cycloalkyl being optionally substituted with -L1-R4; L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0041] In another embodiment, the present invention is directed to one or more compounds independently selected from the following group:
[0042] [ka] (In the formula, L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0043] In certain embodiments, R4 is -NH2, -NCS, -NCO, -N3, alkynyl, cycloalkynyl, -C(O)R 13 , -COOR 13 , -CON(R 13 )2, maleimide, acyl halide, tetrazine, or trans-cyclooctene.
[0044] In certain embodiments, R4 is cyclooctynyl or a cyclooctynyl derivative selected from the group consisting of bicyclononynyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO), and tetramethoxydibenzocyclooctynyl (TMDIBO).
[0045] In certain embodiments, R4 is DBCO or BCN.
[0046] In certain embodiments, R4 comprises a targeting ligand selected from the group consisting of an antibody, an antibody fragment (e.g., an antigen-binding fragment), a binding peptide, a binding polypeptide (e.g., a selective targeting oligopeptide comprising up to 50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety (e.g., an oligonucleotide, a DNA or RNA vector, or an aptamer), and a lectin.
[0047] In certain embodiments, the targeting ligand is an antibody or an antigen-binding fragment thereof.
[0048] In another embodiment, the present invention is a radiometal complex comprising a radiometal ion complexed to a compound of formula I.
[0049] In another embodiment, the present invention relates to a compound of formula (IM + ) radioactive metal complexes:
[0050] [ka] or a pharma- ceutically acceptable salt thereof, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) is a radioactive metal ion selected from the group consisting of R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, the 5- or 6-membered cycloalkyl being optionally substituted with -L1-R4; L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0051] In some embodiments, R4 is -NH2, -NCS, -NCO, -N3, alkynyl, cycloalkynyl, -C(O)R 13 , -COOR 13 , -CON(R 13 )2, maleimide, acyl halide, tetrazine, or trans-cyclooctene.
[0052] In certain embodiments, R4 is cyclooctynyl or a cyclooctynyl derivative selected from the group consisting of bicyclononynyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO), and tetramethoxydibenzocyclooctynyl (TMDIBO).
[0053] In certain embodiments, R4 is DBCO or BCN.
[0054] In certain embodiments, the alpha-emitting radioactive metal ion is actinium-225 (225 Ac).
[0055] In another embodiment, the present invention relates to a compound of formula (IM + or a pharma- ceutically acceptable salt thereof. M + is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) selected from the group consisting of R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, the 5- or 6-membered cycloalkyl being optionally substituted with -L1-R4; L1 is absent or is a linker, R4 is a targeting ligand, where the targeting ligand is selected from the group consisting of an antibody, an antibody fragment (e.g., an antigen-binding fragment), a binding moiety, a binding peptide, a binding polypeptide (e.g., a selective targeting oligopeptide comprising up to 50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety (e.g., an oligonucleotide, a DNA or RNA vector, or an aptamer), and a lectin.
[0056] In certain embodiments, the alpha-emitting radioactive metal ion is actinium-225 ( 225 Ac).
[0057] In another embodiment, the present invention is directed to an immunoconjugate comprising a compound of the present invention covalently attached via R4 to a targeting ligand, preferably an antibody or antigen-binding fragment thereof.
[0058] In a further embodiment, the radioimmunoconjugate comprises a radiometal complex of the invention covalently bound to an antibody or antigen-binding fragment thereof via a triazole moiety.
[0059] In another embodiment, the present invention is directed to a method for preparing an immunoconjugate or radioimmunoconjugate of the present invention comprising covalently linking a compound or radiometal complex of the present invention to a targeting ligand, preferably to an antibody or antigen-binding fragment thereof via R4 of the compound or radiometal complex of the present invention.
[0060] In another embodiment, the present invention is directed to a pharmaceutical composition comprising a compound, immunoconjugate, or radioimmunoconjugate of the present invention and a pharma- ceutical composition may also include one or more pharma- ceutical acceptable carriers.
[0061] In another embodiment, the present invention also provides compositions (e.g., pharmaceutical compositions) and medicaments comprising any one of the compounds described herein (or a pharma- ceutically acceptable salt thereof) and a pharma- ceutically acceptable carrier or one or more excipients or fillers. In a similar embodiment, the present invention also provides compositions (e.g., pharmaceutical compositions) and medicaments comprising any one of the embodiments of the modified antibodies, modified antibody fragments, or modified binding peptides of the present technology disclosed herein and a pharma- ceutically acceptable carrier or one or more excipients or fillers.
[0062] In another embodiment, the present invention is directed to methods of using the radioimmunoconjugates and pharmaceutical compositions of the present invention for targeted radiotherapy.
[0063] In one embodiment, the present invention is directed to a method of selectively targeting tumor cells for radiation therapy in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the present invention.
[0064] In one embodiment, the present invention is directed to a method of treating a neoplastic disease or disorder in a subject in need of such treatment, comprising administering to the subject a pharmaceutical composition of the present invention. [Brief description of the drawings]
[0065] The above Summary of the Invention and the following Detailed Description of the Invention will be better understood when read in conjunction with the appended drawings. It is to be understood that the invention is not limited to the precise embodiments shown in the drawings.
[0066] Of the drawings: [Figure 1A]HPLC chromatograms of chelation studies with La3+ are shown. Figure 1A shows the HPLC chromatograms of 6-((16-((6-carboxypyridin-2-yl)(phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-phenyl) before mixing (top) and after mixing with La3+ (middle). The shift in retention time from 14.137 min to 12.047 min after mixing with La3+ and Ac-225 indicates rapid chelation of La3+. [Figure 1B] HPLC chromatograms of the chelation study with La3+ are shown, and FIG. 1B shows the HPLC chromatograms of TOPA-[C7]-isopentyl before mixing (top) and after mixing with La3+ (bottom). The shift in retention time from 17.181 min to 15.751 min after mixing with La3+ indicates rapid chelation of La3+ and Ac-225 by TOPA-[C7]-isopentyl. [Diagram 2] 2A-2D show schematic diagrams of radiolabeling of antibodies to generate radioimmunoconjugates according to embodiments of the present invention by random conjugation methods (e.g., labeling of lysine residues, cysteine residues, etc.) or site-specific conjugation methods (e.g., glycan-specific, conjugation tag, or engineered cysteine). FIG. 2A shows schematic diagrams of random conjugation by one-step direct radiolabeling. FIG. 2B shows schematic diagrams of random conjugation by click radiolabeling. FIG. 2C shows schematic diagrams of site-specific conjugation by one-step direct radiolabeling. FIG. 2D shows schematic diagrams of site-specific conjugation by click radiolabeling. [Figure 3A]HPLC chromatograms of Ac-225 chelation test are shown. Figure 3A shows the HPLC chromatogram of 6-((16-((6-carboxypyridin-2-yl)(phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-phenyl) chelated with Ac-225 (RA (radioactivity) trace by cut-count-reconstruction). [Figure 3B] HPLC chromatogram of Ac-225 chelation test. Figure 3B shows the HPLC chromatogram of 6-((16-(1-(6-carboxypyridin-2-yl)-4-methylphenyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-isophenyl) chelated with Ac-225 (RA (radioactivity) trace by cut-count-reconstruction). [Figure 4A] HPLC chromatograms of chelation studies with Ac-225 are shown. Figure 4A shows the HPLC chromatogram of TOPA-[C7]-phenylthiourea-H11B6 chelated with Ac-225 (UV). [Figure 4B] HPLC chromatogram of Ac-225 chelation test. Figure 4B shows the HPLC chromatogram of TOPA-[C7]-phenylthiourea-H11B6 chelated with Ac-225 RA (radioactivity) (cut-count-reconstructed RA (radioactivity) trace). [Diagram 5] 1 shows an instant thin layer chromatography (iTLC) scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 12. [Figure 6] 13 shows an iTLC scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 12. [Figure 7]13 shows an iTLC scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 12. [Figure 8] 13 shows an iTLC scan showing the percentage of Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 in the presence of metal impurities, as described in Example 12. [Figure 9] 13 shows an iTLC scan showing the percentage of Ac-225 chelated to DOTA-h11b6 in the presence of metal impurities, as described in Example 12. [Figure 10] 13 shows an iTLC scan showing the percentage of Ac-225 bound to DOTA-h11b6 in the presence of metal impurities, as described in Example 12. [Figure 11] 13 shows an iTLC scan showing the percentage of Ac-225 chelated to DOTA-h11b6 in the presence of metal impurities, as described in Example 12. [Figure 12] 13 shows an iTLC scan showing the percentage of Ac-225 bound to DOTA-h11b6 in the presence of metal impurities, as described in Example 12. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0067] Various publications, articles and patents are cited or described in the "Background" and throughout the specification, and each of these references is incorporated herein by reference in its entirety. The discussion of documents, operations, materials, devices, articles and the like which is included in the specification is for the purpose of providing a context for the present invention. Such discussion is not an admission that any or all of these items constitute part of the prior art to any invention disclosed or claimed.
[0068] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Unless otherwise specified, certain terms cited herein shall have the meanings set forth herein. All patents, published patent applications, and publications cited herein are incorporated by reference as if set forth herein in their entirety.
[0069] The following terms are used throughout as defined below.
[0070] As used herein and in the appended claims, in the context of describing elements (particularly in the context of the claims below), the singular articles "a", "an" and "the" and similar indicators shall be construed to include both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context. The description of ranges of values in the present invention is merely intended to serve as a shorthand way of referring individually to each value falling within the range, unless otherwise indicated herein, and each value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by the context. The use of any and all examples, i.e., exemplary language (e.g., "etc.") provided herein is merely to facilitate easier understanding of the embodiments and does not result in a limitation of the claims unless otherwise claimed. Absence of language in the specification should be construed as indicating an element not included in any claim that is essential.
[0071] In general, a reference to a particular element, such as hydrogen or H, is meant to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium. Thus, tritium, C 14 , P 32 and S 35Compounds containing radioisotopes such as are within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those of skill in the art based on the disclosure herein.
[0072] The term "substituted" means that at least one hydrogen atom is replaced with a non-hydrogen group, provided that all normal valences are maintained and the replacement results in a stable compound. When a particular group is "substituted," the group can have one or more substituents, preferably 1-5 substituents, more preferably 1-3 substituents, and most preferably 1-2 substituents, independently selected from a list of substituents. For example, "substituted" refers to an organic group (e.g., an alkyl group) as defined below, in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to a non-hydrogen or non-carbon atom. Substituted groups also include groups in which one or more bonds to a carbon or hydrogen atom are replaced by a heteroatom with one or more bonds, including double or triple bonds. Thus, unless otherwise specified, a substituted group is substituted with one or more substituents. In some embodiments, a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents. Examples of substituents include halogens (i.e., F, Cl, Br, and I); hydroxyl; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyl (oxo); carboxylates; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; pentafluorosulfanyl (i.e., SF), sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitro groups; nitriles (i.e., CN); and the like. The term "independently," when used with reference to substituents, means that when two or more such substituents are possible, such substituents can be the same or different from one another.
[0073] Substituted ring groups, such as substituted cycloalkyl, aryl, heterocyclyl, and heteroaryl groups, also include rings and ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Thus, substituted cycloalkyl, aryl, heterocyclyl, and heteroaryl groups can also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
[0074] As used herein, C1-C 11 Cm-Cn, such as C1-C8 or C1-C6, when used before a group, refers to the group containing m to n carbon atoms.
[0075] Alkyl groups include straight-chain and branched alkyl groups having 1 to 12 carbon atoms, typically 1 to 10 carbon atoms, or in some embodiments 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Examples of straight-chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. Alkyl groups can be substituted or unsubstituted. Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above, including, but not limited to, haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, and the like.
[0076] Cycloalkyl groups include monocyclic, bicyclic, or tricyclic alkyl groups having 3 to 12 carbon atoms in the ring, or in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms. Exemplary monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, cycloalkyl groups have 3 to 8 ring members, while in other embodiments, the number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7. Bicyclic and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like. Cycloalkyl groups can be substituted or unsubstituted. Substituted cycloalkyl groups can be substituted one or more times with non-hydrogen and non-carbon groups, as defined above. However, substituted cycloalkyl groups also include rings substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4-2,5-, or 2,6-disubstituted cyclohexyl groups, which can be substituted with substituents such as those listed above.
[0077] Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above. In some embodiments, the cycloalkylalkyl group has 4 to 16 carbon atoms, 4 to 12 carbon atoms, typically 4 to 10 carbon atoms. Cycloalkylalkyl groups can be substituted or unsubstituted. Substituted cycloalkylalkyl groups can be substituted at the alkyl portion, the cycloalkyl portion, or both the alkyl and cycloalkyl portions of the group. Representative substituted cycloalkylalkyl groups can be mono-substituted or substituted more than once, for example, but not limited to, mono-, di-, or tri-substituted with the substituents listed above.
[0078] Alkenyl groups include straight and branched chain alkyl groups as defined above, except that at least one double bond is present between two carbon atoms. Alkenyl groups have 2 to 12 carbon atoms, typically 2 to 10 carbon atoms, or in some embodiments, 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, an alkenyl can have one carbon-carbon double bond, or multiple carbon-carbon double bonds, such as 2, 3, 4 or more carbon-carbon double bonds. Examples of alkenyl groups include, but are not limited to, methenyl, ethenyl, propenyl, butenyl, and the like. Alkenyl groups may be substituted or unsubstituted. Representative substituted alkenyl groups may be mono-substituted or substituted more than once, for example, but not limited to, mono-, di-, or tri-substituted with the substituents listed above.
[0079] Cycloalkenyl groups include cycloalkyl groups as defined above, with at least one double bond between two carbon atoms. Cycloalkenyl groups can be monocyclic or polycyclic alkyl groups having 3 to 12, more preferably 3 to 8, carbon atoms in the ring and containing at least one double bond between two carbon atoms. Cycloalkenyl groups can be substituted or unsubstituted. In some embodiments, cycloalkenyl groups can have one, two, or three double bonds, or multiple carbon-carbon double bonds, such as two, three, four, or more carbon-carbon double bonds, but do not include aromatic compounds. Cycloalkenyl groups have 3 to 14 carbon atoms, or in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7, or 8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.
[0080] Cycloalkenylalkyl groups are alkyl groups as defined above, in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Cycloalkenylalkyl groups can be substituted or unsubstituted. Substituted cycloalkenylalkyl groups can be substituted at the alkyl portion, the cycloalkenyl portion, or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups can be substituted one or more times with a substituent such as those listed above.
[0081] Alkynyl groups include straight and branched chain alkyl groups as defined above, except that at least one triple bond is present between two carbon atoms. Alkynyl groups have 2 to 12 carbon atoms, typically 2 to 10 carbon atoms, or in some embodiments, 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, alkynyl groups have one, two, or three carbon-carbon triple bonds. Examples include, but are not limited to, -C=CH, -C=CCH3, -CH2C=CCH3, -C=CCH2CH(CH2CH3)2, among others. Alkynyl groups can be substituted or unsubstituted. A terminal alkyne has at least one hydrogen atom bonded to a triple bonded carbon atom. Representative substituted alkynyl groups may be mono-substituted or substituted more than once, for example, but not limited to, mono-, di-, or tri-substituted with the substituents listed above. A "cyclic alkyne" or "cycloalkynyl" is a cycloalkyl ring containing at least one triple bond between two carbon atoms. Examples of cyclic alkyne or cycloalkynyl groups include, but are not limited to, cyclooctyne, bicyclononyne (BCN), difluorinated cyclooctyne (DIFO), dibenzocyclooctyne (DIBO), keto-DIBO, biarylazacyclooctyne (BARAC), dibenzoazacyclooctyne (DIBAC), dimethoxyazacyclooctyne (DIMAC), difluorobenzocyclooctyne (DIFBO), monobenzocyclooctyne (MOBO), and tetramethoxyDIBO (TMDIBO).
[0082] An aryl group is a cyclic aromatic hydrocarbon that does not contain heteroatoms. Aryl groups herein include monocyclic, bicyclic, and tricyclic ring systems. Thus, aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons, and in other cases, 6-12, or even 6-10 carbon atoms in the ring portion of the group. In some embodiments, an aryl group is phenyl or naphthyl. An aryl group can be substituted or unsubstituted. The phrase "aryl group" includes groups that contain fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, etc.). Representative substituted aryl groups can be mono-substituted or substituted more than once. For example, monosubstituted aryl groups include, but are not limited to, di-, tri-, tetra-, penta-, or hexasubstituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above. Aryl moieties are well known and are described, for example, in Lewis, RJ, ed., Hawley's Condensed Chemical Dictionary, 13 th Edition, John Wiley & Sons, Inc., New York (1997). Aryl groups can be a single ring structure (i.e., monocyclic) or can contain multiple ring structures (i.e., polycyclic) that are fused ring structures. Preferably, the aryl group is a monocyclic aryl group.
[0083] An alkoxy group is a hydroxyl group (-OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above. Examples of linear alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like. Examples of branched alkoxy groups include, but are not limited to, isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like. Examples of cycloalkoxy groups include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. An alkoxy group may be substituted or unsubstituted. Representative substituted alkoxy groups may be substituted one or more times with a substituent such as those listed above.
[0084] Similarly, alkylthio or thioalkoxy refers to the group -SR, where R is an alkyl attached to the parent molecule via a sulfur bridge, e.g., -S-methyl, -S-ethyl, etc. Representative examples of alkylthio include, but are not limited to, -SCH, -SCHCH, and the like.
[0085] As used herein, the term "halogen" refers to bromine, chlorine, fluorine, or iodine. Correspondingly, the term "halo" means fluoro, chloro, bromo, or iodo. In some embodiments, the halogen is fluorine. In other embodiments, the halogen is chlorine or bromine.
[0086] The terms "hydroxy" and "hydroxyl" may be used interchangeably and refer to --OH.
[0087] The term "carboxy" refers to --COOH.
[0088] The term "cyano" refers to --CN.
[0089] The term "nitro" refers to --NO.
[0090] The term "isothiocyanate" refers to -N=C=S.
[0091] The term "isocyanate" refers to --N.dbd.C.dbd.O.
[0092] The term "azido" refers to --N3.
[0093] The term "amino" refers to -NH2. The term "alkylamino" refers to an amino group in which one or both of the hydrogen atoms attached to the nitrogen are replaced with an alkyl group. An alkylamine group can be represented as -NR2, where each R is independently hydrogen or an alkyl group. For example, alkylamines include methylamine (-NHCH3), dimethylamine (-N(CH3)2), -NHCH-2CH3, and the like. As used herein, the term "aminoalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more amino groups. Representative examples of aminoalkyl groups include, but are not limited to, -CH2NH2, -CH2CH2NH2, and -CH2CH(NH2)CH3.
[0094] As used herein, "amide" refers to -C(O)N(R)2, where each R is independently an alkyl group or hydrogen. Examples of amides include, but are not limited to, -C(O)NH2, -C(O)NHCH3, and -C(O)N(CH3)2.
[0095] The terms "hydroxylalkyl" and "hydroxyalkyl" are used interchangeably and refer to an alkyl group substituted with one or more hydroxyl groups. The alkyl can be a branched or straight chain aliphatic hydrocarbon. Examples of hydroxylalkyl include, but are not limited to, hydroxylmethyl (-CHOH), hydroxylethyl (-CHCHOH), and the like.
[0096] As used herein, the term "heterocyclyl" includes stable monocyclic and polycyclic hydrocarbons containing at least one heteroatom ring member, such as sulfur, oxygen, or nitrogen. As used herein, the term "heteroaryl" includes stable monocyclic and polycyclic aromatic hydrocarbons containing at least one heteroatom ring member, such as sulfur, oxygen, or nitrogen. Heteroaryl can be monocyclic or polycyclic, e.g., bicyclic or tricyclic. Each ring of a heteroatom-containing heterocyclyl or heteroaryl group can contain one or two oxygen or sulfur atoms and / or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less, and each ring has at least one carbon atom. Heteroaryl groups that are polycyclic, e.g., bicyclic or tricyclic, must contain at least one fully aromatic ring, but other fused rings or rings can be aromatic or non-aromatic. The heterocyclyl or heteroaryl group can be attached to any available nitrogen or carbon atom of any ring of the heterocyclyl or heteroaryl group. Preferably, the term "heteroaryl" refers to 5- or 6-membered monocyclic and 9- or 10-membered bicyclic groups having at least one heteroatom (O, S, or N) in at least one of the rings, with the heteroatom-containing ring preferably having 1, 2, or 3 heteroatoms, more preferably having 1 or 2 heteroatoms selected from O, S, and / or N. The nitrogen heteroatom of a heteroaryl can be substituted or unsubstituted. Additionally, the nitrogen and sulfur heteroatoms of a heteroaryl can be optionally oxidized (i.e., N→O and S(O)). r where r is 0, 1 or 2.
[0097] The term "ester" refers to -C(O)R, where R is alkyl.
[0098] The term "carbamate" refers to -OC(O)NR2, where each R is independently alkyl or hydrogen.
[0099] The term "aldehyde" refers to -C(O)H.
[0100] The term "carbonate" refers to -OC(O)OR, where R is alkyl.
[0101] The term "maleimide" refers to a group having the chemical formula H2C2(CO)2NH. The term "maleimide" refers to a maleimide group covalently bonded to another group or molecule. Preferably, the maleimide group is N-bonded, for example:
[0102] [ka]
[0103] The term "acyl halide" refers to -C(O)X, where X is halo (e.g., Br, Cl). Exemplary acyl halides include acyl chlorides (-C(O)Cl) and acyl bromides (-C(O)Br).
[0104] According to the convention used in the art,
[0105] [ka] is used in structural formulas herein to indicate a bond that is the point of attachment of a moiety, functional group, or substituent to a core, parent, or backbone structure, such as a compound of the invention or a targeting ligand.
[0106] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0 to 3 R groups, that group may be optionally substituted with up to 3 R groups, and each occurrence of R is independently selected from the definitions of R.
[0107] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring.
[0108] As used herein, the term "radioactive metal ion" or "radioactive metal ion" refers to one or more isotopes of an element that emit particles and / or photons. Any radioactive metal ion known to those of skill in the art in light of the present disclosure can be used in the present invention. Examples of radioactive metal ions suitable for use in the present invention include: 47 Sc, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, 89 Sr, 90 Y, 99 Tc, 105 Rh, 109 Pd, 111 Ag, 111 In, 117 Sn, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 159 Gd, 165 Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 227 Th, and 255 Preferably, the radioactive metal ion is a "therapeutic emitter", which means a radioactive metal ion useful in therapeutic applications. Examples of therapeutic emitters include beta emitters or alpha emitters, e.g., 132 La, 135 La, 134 Ce, 144 Nd, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 159 Gd, 165Dy, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 194 Ir, 198 Au, 199 Au, 211 At, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 225 Ac, 255 Fm and 227 Th, 226 Th, 230 Preferably, the radioactive metal ion used in the present invention is an alpha-emitting radioactive metal ion, such as actinium 225 ( 225 Ac).
[0109] The compounds of the present invention refer to macrocyclic compounds to which metals, preferably radioactive metals, can be complexed. In certain embodiments, the compounds are macrocyclic or macrocyclic rings that contain one or more heteroatoms, such as oxygen and / or nitrogen, as ring atoms. Preferably, the compounds are macrocyclic rings that are derivatives of 4,13-diaza-18-crown-6.
[0110] As used herein, a "radioactive metal complex" refers to a complex comprising a radioactive metal ion associated with a macrocycle compound. The radioactive metal ion is bound or coordinated to the macrocycle by a coordinate bond. Heteroatoms of the macrocycle may participate in the coordinate bonding of the radioactive metal ion to the macrocycle compound. The macrocycle compound may be substituted with one or more substituents that may also participate in the coordinate bonding of the radioactive metal ion to the macrocycle compound in addition to or instead of heteroatoms of the macrocycle.
[0111] As used herein, the term "TOPA" refers to the macrocycle known in the art as H2bp18c6, which may alternatively be referred to as N,N'-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown-6. For example, see Roca-Sabio et al., "Macrocyclic Receptor Exhibiting Unprecedented Selectivity for Light Lanthanides," J.Am.Chem.Soc.(2009)131,3331-3341, incorporated herein by reference.
[0112] As used herein, the term "click chemistry" refers to a chemical principle introduced by Sharpless that describes tailored chemistry to rapidly and reliably generate covalent bonds by linking together small units that contain reactive groups (see Kolb, et al., Angewandte Chemie International Edition (2001) 40:2004-2021). Click chemistry does not refer to a specific reaction, but rather to a concept that includes, but is not limited to, reactions that mimic reactions found in nature. In some embodiments, click chemistry reactions are modular, have a wide range, give high chemical yields, produce inactive by-products, are stereospecific, exhibit large thermodynamic driving forces that favor reactions with a single reaction product, and / or can be performed under physiological conditions. In some embodiments, click chemistry reactions can be performed under simple reaction conditions, use readily available starting materials and reagents, use non-toxic solvents or use innocuous or easily removed solvents such as water, and / or provide simple product isolation by non-chromatographic methods such as crystallization or distillation.
[0113] Click chemistry reactions utilize reactive groups that are rarely found in naturally occurring biomolecules and are chemically inert to biomolecules, but when click chemistry partners are reacted together, the reaction can occur efficiently under biologically relevant conditions, such as cell culture conditions, without the presence of excessive heat and / or harsh reagents. In general, click chemistry reactions require at least two molecules, including click reaction partners that can react with each other. Such click reaction partners that are reactive with each other may be referred to herein as click chemistry handle pairs, or click chemistry pairs. In some embodiments, the click reaction partners are azides and strained alkynes, such as cycloalkynes, such as cyclooctyne or cyclooctyne derivatives, or any other alkynes. In other embodiments, the click reaction partners are reactive dienes and suitable tetrazine dienophiles. For example, trans-cyclooctene, norbornene, or biscyclononene can be paired with suitable tetrazine dienophiles as click reaction pairs. In yet other embodiments, tetrazole can act as a potential source of nitrile imines that can be paired with unactivated alkenes in the presence of UV light to create click reaction pairs, referred to as "photo-click" reaction pairs. In other embodiments, the click reaction partners are cysteine and maleimide. For example, a cysteine from a peptide (e.g., GGGC (SEQ ID NO: 23)) can be reacted with a maleimide associated with a chelator (e.g., NOTA). Other suitable click chemistry handles are known to those of skill in the art (see, e.g., Spicer et al., Selective chemical protein modification. Nature Communications. 2014;5:p.4740). In other embodiments, the click reaction partners are Staudinger ligation components, such as phosphines and azides.In other embodiments, the click reaction partners are Diels-Alder reaction components such as dienes (e.g., tetrazines) and alkenes (e.g., trans-cyclooctene (TCO) or norbornene). Exemplary click reaction partners are described in U.S. Patent Publication No. 20130266512 and WO2015073746, the relevant descriptions of which are incorporated herein by reference.
[0114] According to a preferred embodiment, the click chemistry reaction utilizes an azide group and an alkyne group, more preferably a strained alkyne group, such as a cycloalkyne, such as a cyclooctyne or a cyclooctyne derivative, as a click chemistry pair or reaction partner. In such an embodiment, the click chemistry reaction is a Huisgen cycloaddition or a 1,3-dipolar cycloaddition between an azide (-N3) and an alkyne moiety to form a 1,2,3-triazole linker. The click chemistry reaction between an alkyne and an azide typically requires the addition of a copper catalyst to promote the 1,3-cycloaddition reaction, and is known as the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. However, click chemistry reactions between cyclooctyne or cyclooctyne derivatives and azides typically do not require the addition of a copper catalyst, but instead proceed via a strain-promoted azide-alkyne cycloaddition (SPAAC) reaction (Debets, MF, et al., Bioconjugation with strained alkenes and alkynes. Acc Chem Res, 2011. 44(9): p. 805-15).
[0115] As used herein, the term "targeting ligand" refers to any molecule that enhances affinity for a selected target, such as an antigen, cell, cell type, tissue, organ, region of the body, or compartment (e.g., a cell, tissue, or organ compartment). Targeting ligands include, but are not limited to, antibodies or antigen-binding fragments thereof, aptamers, polypeptides, and scaffold proteins. Preferably, the targeting ligand is a polypeptide, more preferably an antibody or antigen-binding fragment thereof, an engineered domain, or a scaffold protein.
[0116] As used herein, the term "antibody" or "immunoglobulin" is used in a broad sense and includes immunoglobulin or antibody molecules, including polyclonal antibodies, monoclonal antibodies, including murine, human, human-adapted, humanized, and chimeric monoclonal antibodies, and antigen-binding fragments thereof.
[0117] In general, an antibody is a protein or peptide chain that exhibits binding specificity for a specific antigen (herein referred to as "target"). The structure of an antibody is well known. Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG, and IgM, depending on the amino acid sequence of the heavy chain constant domain. IgA and IgG are further subclassified as isotypes IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4. Antibodies used in the present invention can be of any of the five major classes or corresponding subclasses. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequence of their constant domain. According to certain embodiments, antibodies used in the present invention include heavy and / or light chain constant regions of murine or human antibodies. Each of the four IgG subclasses has a distinct biological function known as effector function. These effector functions are generally mediated by interaction with Fc receptors (FcγR) or by binding of C1q and fixation of complement. Binding to FcγR can result in antibody-dependent cell-mediated cytolysis, whereas binding to complement factors can result in complement-mediated cytolysis. Antibodies useful in the present invention may have no or minimal effector functions but retain their ability to bind FcRn.
[0118] As used herein, the term "antigen-binding fragment" refers to an antibody fragment, such as, for example, a diabody, Fab, Fab', F(ab')2, Fv fragment, disulfide-stabilized Fv fragment (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabody (ds diabody), single-chain antibody molecule (scFv), single domain antibody (sdab), scFv dimer (bivalent diabody), multispecific antibody formed from a portion of an antibody containing one or more CDRs, camelized single domain antibody, nanobody, domain antibody, bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not contain a complete antibody structure. An antigen-binding fragment can bind to the same antigen to which the parent antibody or parent antibody fragment binds. As used herein, the term "single-chain antibody" refers to a single-chain antibody, as previously known in the art, that contains a heavy chain variable region and a light chain variable region connected by a short peptide of about 15 to about 20 amino acids. As used herein, the term "single domain antibody" refers to a single domain antibody conventionally known in the art that comprises a heavy chain variable region and a heavy chain constant region, or that comprises only a heavy chain variable region.
[0119] As used herein, the term "scaffold" or "scaffold protein" refers to any protein that has a target binding domain and can bind to a target. A scaffold includes a "framework" that is mostly structural, and a "binding domain" that contacts the target and provides specific binding. The binding domain of a scaffold does not have to be defined by one continuous sequence of the scaffold. In certain cases, a scaffold may be part of a larger binding protein, which itself may be part of a multimeric binding protein that includes multiple scaffolds. Certain binding proteins may be bispecific or multispecific in that they can bind to two or more different epitopes. A scaffold may be derived from a single chain antibody, or the scaffold may not be derived from an antibody.
[0120] As used herein, the term "aptamer" refers to a single-stranded oligonucleotide (a single-stranded DNA or RNA molecule) that can specifically bind to its target with high affinity. Aptamers can be used as targeting molecules for a variety of organic and inorganic substances.
[0121] Pharmaceutically acceptable salts of the compounds described herein are within the scope of the present technology and include acid or base addition salts that retain the desired pharmacological activity and are not biologically undesirable (e.g., the salts are not overly toxic, allergenic, or irritating and are bioavailable). When the compounds of the present technology have a basic group, such as an amino group, they can form pharma- ceutically acceptable salts with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, and p-toluenesulfonic acid), or acidic amino acids (e.g., aspartic acid and glutamic acid). When the compounds of the present technology have an acidic group, such as a carboxylic acid group, they can form pharma-ceutically acceptable salts with alkali metals and alkaline earth metals (e.g., Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ Salts can be formed with metals such as dimethylaminoethyl amine, ...
[0122] Those skilled in the art will understand that the compounds of the present technology may exhibit the phenomenon of tautomerism, conformational isomerism, geometric isomerism, and / or stereoisomerism.The drawings of formulae in this specification and claims may represent only one of the possible tautomeric, conformational isomerism, stereoisomeric, or geometric isomerism, so it should be understood that the present technology encompasses any tautomeric, conformational isomerism, stereoisomeric, and / or geometric isomerism of the compounds having one or more of the utilities described herein, as well as mixtures of these various different forms.
[0123] Stereoisomers (also called optical isomers) of a compound include all chiral, diastereomeric, and racemic forms of a structure unless a specific stereochemistry is explicitly indicated. Thus, the compounds used in the present technology include enriched or resolved optical isomers at any or all asymmetric atoms, as is clear from the depiction. Both racemic and diastereomeric mixtures, as well as individual optical isomers, can be isolated or synthesized to be substantially free of their enantiomeric or diastereomeric partners, and all of these stereoisomers are within the scope of the present technology.
[0124] The present technology provides new macrocyclic complexes that are substantially more stable than those of the prior art. Thus, these new complexes can advantageously target cancer cells more effectively, and are substantially less toxic to non-targeted tissues than the complexes of the prior art. Furthermore, the new complexes can be advantageously prepared at room temperature, in contrast to DOTA-type complexes, which generally require high temperatures (e.g., at least 80°C) for complexation with radionuclides. The present technology also specifically uses alpha-emitting radionuclides instead of beta-emitting radionuclides. Alpha-emitting radionuclides are much more energetic than beta-emitting radionuclides, and therefore substantially more powerful.
[0125] Although certain embodiments have been illustrated and described, one of ordinary skill in the art, after reading the foregoing specification, may make modifications, equivalent substitutions, and other types of alterations to the compounds of the present technology described herein or their salts, pharmaceutical compositions, derivatives, prodrugs, metabolites, tautomers, or racemic mixtures. Each of the above aspects and embodiments may also include or incorporate the variations or aspects disclosed with respect to any or all of the other aspects and embodiments.
[0126] The present technology is not limited with respect to the specific embodiments described herein, which are intended as single descriptions of individual aspects of the technology. Many modifications and variations of the present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods within the scope of the present technology will be apparent to those skilled in the art from the foregoing description, in addition to those recited herein. Such modifications and variations are intended to fall within the scope of the appended claims. It is to be understood that the present technology is not limited to specific methods, reagents, compounds, compositions, labeled compounds, or biological systems, which can, of course, vary. It is also to be understood that the terms used herein are for the purpose of describing particular embodiments only, and are not intended to be limiting. Thus, it is intended that the specification be considered only as exemplary, with the breadth, scope, and spirit of the present technology being indicated only by the appended claims, the definitions therein, and any equivalents thereof.
[0127] Although the embodiments are illustratively disclosed herein, they may suitably be practiced in the absence of any element or limitation not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like, are to be understood expansively and without limitation. Furthermore, the terms and expressions used herein are used for purposes of description and not limitation, and there is no intention in the use of such terms and expressions to exclude any equivalents of the features (or portions thereof) shown and described, recognizing that various modifications are possible within the scope of the claimed technology. Furthermore, the phrase "consisting essentially of" is understood to include the elements specifically recited and additional elements that do not materially affect the basic and novel characteristics of the claimed technology. The phrase "consisting of" excludes any elements not specified.
[0128] All publications, patent applications, issued patents, and other documents (e.g., journals, articles, and / or textbooks) mentioned herein are incorporated by reference herein as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions contained in the texts incorporated by reference are excluded to the extent they conflict with definitions in this disclosure.
[0129] In one embodiment of the present invention, intermediate compound 14
[0130] [ka] or a pharma- ceutically acceptable salt or solvate thereof, the process for preparing said compound comprises the steps of:
[0131] [ka] reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof at a temperature ranging from ambient temperature to −78° C. to obtain compound 2;
[0132] [ka] reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 3;
[0133] [ka] reacting 3 with 2 in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate);
[0134] [ka] reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 in an organic solvent or mixture thereof under reducing conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 7;
[0135] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate);
[0136] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 9;
[0137] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10;
[0138] [ka] reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain 13, which is reacted with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14.
[0139] In another embodiment of the present invention, compound 14
[0140] [ka] or a pharma- ceutically acceptable salt or solvate thereof, the preferred synthetic steps are as follows:
[0141] [ka] reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof at a temperature ranging from ambient temperature to −78° C. to obtain compound 2;
[0142] [ka] reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 3;
[0143] [ka] reacting 3 with 2 in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate);
[0144] [ka] reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 in an organic solvent or mixture thereof under reducing conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 7;
[0145] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate);
[0146] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 9;
[0147] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10;
[0148] [ka] reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain 13, which is reacted with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14.
[0149] In a further embodiment, compound 10
[0150] [ka] or a pharma- ceutically acceptable salt or solvate thereof, can be prepared by the steps of:
[0151] [ka] Compound 9 is prepared by a process comprising reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., stirring for 5 to 60 minutes, and reacting the same with trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 10.
[0152] Removal of the t-butoxycarbonyl protecting group proved difficult and many conditions were tried without success. Attempts were made under acidic and basic conditions (HCl, TFA, MSA, phosphoric acid, KOAc / AcOH, TsCl-DMAP, BF3, OEt2, TMSCl, and CsCO3), all of which resulted in rapid decomposition.
[0153] To overcome this synthetic challenge, it was determined that the conditions and reagents used in the t-butoxycarbonyl deprotection step were successfully achieved using BSA and TMSOTf reagents. The use of mild conditions of BSA and TMSOTf reagents was unexpected and gave compound 10.
[0154] One embodiment of the present invention is a compound of formula (14)
[0155] [ka] or a pharma- ceutically acceptable salt or solvate thereof.
[0156] Another embodiment of the present invention is a compound of formula (11)
[0157] [ka] or a pharma- ceutically acceptable salt or solvate thereof.
[0158] Another aspect of the present invention is intermediate compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt).
[0159] [ka] or a pharma- ceutically acceptable salt or solvate thereof.
[0160] One embodiment of the present invention is compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt).
[0161] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0162] [ka] reacting compound 10 with sodium hydroxide in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 11;
[0163] [ka] reacting compound 11 with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 12.
[0164] Additionally, the present invention encompasses compounds capable of forming complexes with the radiometals, radiometal complexes, and radioimmunoconjugates described herein.
[0165] Compounds of the present invention (macrocyclic compounds) In one embodiment, the present invention provides a compound of formula (I):
[0166] [ka] or a pharma- ceutically acceptable salt thereof, R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, the 5- or 6-membered cycloalkyl being optionally substituted with -L1-R4; L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0167] In some embodiments, L is absent. When L is absent, R is directly bonded to the compound (e.g., via a covalent bond).
[0168] In some embodiments, L1 is a linker. As used herein, the term "linker" refers to a chemical moiety that connects the compounds of the present invention to a nucleophilic moiety, an electrophilic moiety, or a targeting ligand. In view of the present disclosure, any suitable linker known to one of skill in the art can be used in the present invention. The linker can be, for example, a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl moiety, a substituted or unsubstituted aryl or heteroaryl, a polyethylene glycol (PEG) linker, a peptide linker, a sugar-based linker, or a cleavable linker, for example, a disulfide bond or a protease cleavage site, for example, valine-citrulline-p-aminobenzyl (PAB). Exemplary linker structures suitable for use in the present invention include:
[0169] [ka] In the formula, m is an integer of 0 to 12, but is not limited thereto.
[0170] In some embodiments, R4 is a nucleophilic moiety or an electrophilic moiety. A "nucleophilic moiety" or "nucleophilic group" refers to a functional group that donates an electron pair to form a covalent bond in a chemical reaction. An "electrophilic moiety" or "electrophilic group" refers to a functional group that accepts an electron pair to form a covalent bond in a chemical reaction. A nucleophilic group reacts with an electrophilic group to form a new covalent bond in a chemical reaction, and vice versa. The nucleophilic or electrophilic group of the compound of the present invention can be reacted with a targeting ligand or other chemical moiety (e.g., a linker) including a corresponding reaction partner, thereby allowing the targeting ligand or chemical moiety to be covalently attached to the compound of the present invention.
[0171] Illustrative examples of nucleophilic groups include, but are not limited to, azides, amines, and thiols. Illustrative examples of electrophilic groups include, but are not limited to, amine-reactive groups, thiol-reactive groups, alkynyls, and cycloalkynyls. Amine-reactive groups preferably react with primary amines, including those present at the N-terminus of each polypeptide chain and in the side chains of lysine residues. Examples of amine-reactive groups suitable for use in the present invention include, but are not limited to, N-hydroxy succinimide (NHS), substituted NHS (such as sulfo-NHS), isothiocyanate (-NCS), isocyanate (-NCO), esters, carboxylic acids, acyl halides, amides, alkylamides, and tetrafluorophenyl esters and perfluorophenyl esters. Thiol-reactive groups react with thiols or sulfhydryls, preferably with thiols present in the side chains of cysteine residues of polypeptides. Examples of thiol-reactive groups suitable for use in the present invention include, but are not limited to, Michael acceptors (e.g., maleimides), haloacetyls, acyl halides, activated disulfides, and phenyloxadiazole sulfones.
[0172] In certain embodiments, R4 is -NH2, -NCS (isothiocyanate), -NCO (isocyanate), -N3 (azide), alkynyl, cycloalkynyl, carboxylic acid, ester, amide, alkylamide, maleimide, acyl halide, tetrazine, or trans-cyclooctene, more specifically, -NCS, -NCO, -N3, alkynyl, cycloalkynyl, -C(O)R 13 , -COOR 13 , -CON(R 13 )2, maleimide, acyl halide (e.g., —C(O)Cl, —C(O)Br), tetrazine, or trans-cyclooctene, where each R 13 is independently hydrogen or alkyl.
[0173] In some embodiments, R4 is an alkynyl group, a cycloalkynyl group, or an azide group, which allows the compound of the present invention to be linked to a targeting ligand or other chemical moiety (e.g., a linker) using a click chemistry reaction. In such embodiments, the click chemistry reaction that can be carried out is a Huisgen cycloaddition or a 1,3-dipolar cycloaddition between an azide (-N3) and an alkynyl group or a cycloalkynyl group to form a 1,2,4-triazole linker or moiety. In one embodiment, the compound of the present invention comprises an alkynyl group or a cycloalkynyl group, and the targeting ligand or other chemical moiety comprises an azide group. In another embodiment, the compound of the present invention comprises an azide group, and the targeting ligand or other chemical moiety comprises an alkynyl group or a cycloalkynyl group.
[0174] In certain embodiments, R4 is an alkynyl group, more preferably a terminal alkynyl group or a cycloalkynyl group that is particularly reactive with azide groups via strain-promoted azide-alkyne cyclocycloaddition (SPAAC). Examples of cycloalkynyl groups that can react with azide groups via SPAAC include, but are not limited to, cyclooctynyl or bicyclononyl (BCN), difluorinated cyclooctynyl (DIFO), dibenzocyclooctynyl (DIBO), keto-DIBO, biarylazacyclooctynonyl (BARAC), dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO), dimethoxyazacyclooctynyl (DIMAC), difluorobenzocyclooctynyl (DIFBO), monobenzocyclooctynyl (MOBO) and tetramethoxydibenzocyclooctynyl (TMDIBO).
[0175] In certain embodiments, R4 is dibenzoazacyclooctynyl (DIBAC, DBCO, ADIBO) having the following structure:
[0176] [ka] In embodiments where R4 is DBCO, the DBCO can be covalently bound to the compound directly or indirectly via a linker, and is preferably bound to the compound indirectly via a linker.
[0177] In certain embodiments, R4 is a targeting ligand. The targeting ligand can be directly bound to the compound by a covalent bond or indirectly bound to the compound via a linker. The targeting ligand can be a polypeptide, such as an antibody or an antigen-binding fragment thereof, an aptamer, or a scaffold protein. In a preferred embodiment, the targeting ligand is an antibody or an antigen-binding fragment thereof, such as a monoclonal antibody (mAb) or an antigen-binding fragment thereof, which specifically binds to an antigen associated with a tumor disease or disorder, such as a cancer antigen, which can be prostate-specific membrane antigen (PSMA), BCMA, Her2, EGFR, KLK2, CD19, CD22, CD30, CD33, CD79b, or Nectin-4.
[0178] According to certain embodiments, the targeting ligand specifically binds to a prostate specific antigen (eg, PSMA or KLK2).
[0179] In another embodiment, the present invention provides a compound of formula (II):
[0180] [ka] or a pharma- ceutically acceptable salt thereof, L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0181] In another embodiment, the present invention provides a compound of formula (III):
[0182] [ka] or a pharma- ceutically acceptable salt thereof, L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0183] In another embodiment, the present invention is directed to a compound, wherein R1 is -L1-R4, R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, L1 is absent or is a linker, and R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand); or a pharma-ceutically acceptable salt thereof.
[0184] In a further embodiment, the present invention is directed to a compound, wherein R1 is H, and R2 and R3, together with the carbon atom to which they are attached, form a 5- or 6-membered cycloalkyl substituted with -L1-R4, where L1 is absent or is a linker, and R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand; or a pharma-ceutically acceptable salt thereof.
[0185] Further embodiments include those in which R4 is a targeting ligand, the targeting ligand being selected from the group consisting of an antibody, an antigen-binding fragment of an antibody, a scaffold protein, and an aptamer.
[0186] In one embodiment, the compound of the invention is
[0187] [ka]
[0188] [ka] wherein n is 1 to 10.
[0189] The compounds can be covalently attached to a targeting ligand (e.g., an antibody or antigen-binding fragment thereof) to form an immunoconjugate or radioimmunoconjugate (when complexed with a metal) by reacting the compound with an azide-labeled targeting ligand to form a 1,2,3-triazole linker via a click chemistry reaction, described in more detail below.
[0190] The compounds of the invention can be prepared by any method known in the art in light of this disclosure. For example, the pendant aromatic / heteroaromatic groups can be attached to the macrocycle moiety by methods known in the art, such as those illustrated and described below.
[0191] Radioactive metal complexes In certain embodiments, the present invention is directed to radiometal complexes comprising a radiometal ion complexed to a compound of the present invention by a coordinate bond. Any of the compounds of the present invention described herein can include a radiometal ion. Preferably, the radiometal ion is an alpha-emitting radiometal ion, more preferably 225 The compounds of the present invention can be used to react with radioactive metal ions, particularly radioactive metal ions, at any specific activity, regardless of metal impurities. 225 It is capable of chelating Ac, thus forming radiometal complexes that have high chelating stability in vivo and in vitro and are stable to challenge agents such as diethylene triamine pentaacetic acid (DTPA).
[0192] In certain embodiments, the present invention provides a compound of formula (IM + ) radioactive metal complex structure:
[0193] [ka] or a pharma- ceutically acceptable salt thereof, M + is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) selected from the group consisting of R1 is hydrogen and R2 is -L1-R4; Alternatively, R1 is -L1-R4 and R2 is hydrogen; R3 is hydrogen; or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl, the 5- or 6-membered cycloalkyl being optionally substituted with -L1-R4; L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0194] In another embodiment, the present invention relates to a compound of formula (II-M + ) radioactive metal complexes:
[0195] [ka] or a pharma- ceutically acceptable salt thereof, M + is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) selected from the group consisting of L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0196] In another embodiment, the present invention relates to a compound of formula (III-M + ) radioactive metal complexes:
[0197] [ka] or a pharma- ceutically acceptable salt thereof, M + is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 (132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U), L1 is absent or a linker; R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand.
[0198] In another embodiment, the present invention provides a compound comprising: M + is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) selected from the group consisting of R1 is -L1-R4, R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl; L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand; or a pharma- ceutically acceptable salt thereof.
[0199] In a further embodiment, the present invention provides a compound comprising: M +is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) selected from the group consisting of R1 is H or R2 and R3 together with the carbon atom to which they are attached form a 5- or 6-membered cycloalkyl substituted with -L1-R4; L1 is absent or is a linker, R4 is a nucleophilic moiety, an electrophilic moiety, or a targeting ligand; or a pharma- ceutically acceptable salt thereof.
[0200] In a particular embodiment, the present invention provides a method for producing
[0201] [ka]
[0202] [ka] wherein n is 1 to 10, and M +is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U).
[0203] The radioactive metal complexes can be prepared by any method known in the art in view of the present disclosure. For example, the macrocycle compounds of the present invention can be mixed with a radioactive metal ion and the mixture can be incubated to form the radioactive metal complex. In one exemplary embodiment, the compounds can be 225 It was mixed with a solution of Ac(NO3)3 and bonded to the compound via coordinate bonds. 225 As noted above, the compounds of the present invention form radioactive complexes with radiometals, particularly 225 Thus, in certain embodiments, the compounds of the present invention are combined with the compounds of the present invention at a ratio of 1:1000, 1:500, 1:400, 1:300, 1:200, 1:100, 1:50, 1:10, or 1:5, preferably 1:5 to 1:200, more preferably 1:5 to 1:100. 225 In terms of concentration ratio with Ac ions, 225Ac ions. Thus, in some embodiments, the compounds of the present invention can be used to form radioactive metal complexes. 225 The ratio of Ac to other known 225 This is much lower than the ratio achievable with Ac chelators (e.g., DOTA). The radiocomplexes can be characterized by instant thin layer chromatography (e.g., iTLC-SG), HPLC, LC-MS, etc. Exemplary methods are described herein, e.g., in the Examples below.
[0204] Immunoconjugates and radioimmunoconjugates In another embodiment, the present invention is directed to immunoconjugates and radioimmunoconjugates. The compounds of the present invention and the radiometal complexes of the present invention can be conjugated (i.e., covalently attached) to targeting ligands, such as immunological agents, to generate immunoconjugates and / or radioimmunoconjugates suitable for medical applications in subjects (e.g., humans), such as targeted radiotherapy. The macrocycle compounds, radiometal complexes and radioimmunoconjugates of the present invention can be used to specifically label targeting ligands, in particular antibodies or antigen-binding fragments thereof, capable of specifically binding to a target of interest (such as cancer cells), with radioactive metal ions to generate radioimmunoconjugates. In particular, the compounds of the present invention and / or the radiometal complexes of the present invention can be used to specifically label radioactive metal ions, in particular antibodies or antigen-binding fragments thereof, capable of specifically binding to a target of interest (such as cancer cells), with radioactive metal ions to generate radioimmunoconjugates. 225 Radioimmunoconjugates with high yield complexation of Ac and desired compound-to-antibody ratios (CAR) can be generated.
[0205] According to certain embodiments, the methods of the invention provide an average CAR of less than 10, less than 8, less than 6, or less than 4, or a CAR of from about 2 to about 8, or from about 2 to about 6, or from about 2 to about 4, or from about 2 to about 3, or a CAR of about 2, or about 3, or about 4, or about 5, or about 6, or about 7, or about 8.
[0206] As used herein, an "immunoconjugate" is an antibody or antigen-binding fragment thereof conjugated (e.g., covalently linked) to a second molecule, such as a toxin, a drug, a radioactive metal ion, a radioactive metal complex, etc. A "radioimmunoconjugate" (sometimes also called a radioconjugate) is specifically an immunoconjugate in which an antibody or antigen-binding fragment thereof is labeled with a radioactive metal or conjugated to a radioactive metal complex.
[0207] In certain embodiments of the invention, the immunoconjugate comprises a compound of the invention (e.g., a compound of formula (I) as described herein) covalently attached to an antibody or antigen-binding fragment thereof, preferably via a linker. Depending on the reactive functional groups (i.e., nucleophilic and electrophilic) on the compound of formula (I) and the antibody or antigen-binding fragment thereof, many conjugation configurations are possible with various linkages between the compound of the invention and the antibody or antigen-binding fragment thereof.
[0208] In certain embodiments of the invention, a radioimmunoconjugate comprises a radiometal complex of the invention, e.g., a radiometal complex described herein, covalently attached, preferably via a linker, to an antibody or antigen-binding fragment thereof.
[0209] Any of the compounds or radiometal complexes of the invention described herein can be used to produce an immunoconjugate or radioimmunoconjugate of the invention.
[0210] In certain embodiments, the radiometal complexes or radioimmunoconjugates of the present invention comprise an alpha-emitting radiometal ion coordinated to the compound portion of the radiocomplex. Preferably, the alpha-emitting radiometal ion is 225 It is Ac.
[0211] In certain embodiments, the antibody or antigen-binding fragment in the immunoconjugate or radioimmunoconjugate of the present application can specifically bind to a tumor antigen. Preferably, the antibody or antigen-binding fragment specifically binds to a cancer antigen. Examples of cancer antigens include, but are not limited to, prostate-specific membrane antigen (PSMA), BCMA, Her2, EGFR, KLK2, CD19, CD22, CD30, CD33, CD79b, and Nectin-4.
[0212] In one embodiment, the antibody specifically binds to PSMA. Preferably, the antibody is PSMB127. The human IgG4 antibody that binds to human prostate-specific membrane antigen (PSMA), referred to herein as "anti-PSMA mAb" and designated as "PSMB127", has a heavy chain (HC) CDR1 sequence of SEQ ID NO: 3, a HC CDR2 sequence of SEQ ID NO: 4, a HC CDR3 sequence of SEQ ID NO: 5, a light chain (LC) CDR1 sequence of SEQ ID NO: 6, a LC CDR2 sequence of SEQ ID NO: 7, and a LC CDR3 sequence of SEQ ID NO: 8, and has a HC sequence of SEQ ID NO: 9 and a LC sequence of SEQ ID NO: 10. The anti-PSMA mAb was expressed and purified using standard chromatographic methods. The antibody PSMB127, its biological activity, its uses, or other related information are described, for example, in US Patent Publication No. 20200024360(A1), the contents of which are incorporated herein by reference in their entirety.
[0213] In another embodiment, the antibody specifically binds to human kallikrein 2 (KLK2). KLK2 is sometimes referred to as hK2. Preferably, the antibody is H11B6 (also referred to as h11B6). H11B6 antibody, biological activity, uses, or other related information is described in U.S. Patent No. 10,100,125, the contents of which are incorporated herein by reference in their entirety. As described herein, the H11B6 antibody polypeptide comprises a heavy chain (HC) variable region comprising the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and a light chain (LC) variable region comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16.
[0214] Thus, according to a particular embodiment, the radioconjugate of the present invention comprises the h11B6 antibody, which comprises (a) a heavy chain variable region (VH) comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 11 (SDYAWN), a VH CDR2 having the amino acid sequence of SEQ ID NO: 12 (YISYSGSTTYNPSLKS), and a VH CDR3 having the amino acid sequence of SEQ ID NO: 13 (GYYYGSGF), and (b) a light chain variable region (VL) comprising a VL CDR1 having the amino acid sequence of SEQ ID NO: 14 (KASESVEYFGTSLMH), a VL CDR2 having the amino acid sequence of SEQ ID NO: 15 (AASNRES), and a VL CDR3 having the amino acid sequence of SEQ ID NO: 16 (QQTRKVPYT).
[0215] The anti-H11B6 antibody may further comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, or a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 19 and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 20, or a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 21 and a light chain constant region comprising the amino acid sequence of SEQ ID NO: 22.
[0216] The Kabat numbering scheme (Kabat et al., 1991) is used throughout this description (Sequences of Immunological Interest, 5th edition, NIH, Bethesda, Md., the disclosure of which is incorporated herein by reference).
[0217] According to certain embodiments, the antibodies of the invention comprise a heavy chain variable region (VH) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 17, and / or a light chain variable region (VL) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 18.
[0218] According to certain embodiments, an antibody of the invention comprises a heavy chain constant region having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 19, and / or a light chain constant region having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO:20.
[0219] According to certain embodiments, an antibody of the invention comprises a heavy chain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO:21, and / or a light chain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence of SEQ ID NO:22.
[0220] According to certain embodiments, an antibody of the invention (eg, h11B6) comprises or consists of an intact (ie, complete) antibody, such as an IgA, IgD, IgE, IgG, or IgM molecule.
[0221] According to certain embodiments, the antibodies of the invention (e.g., h11B6) comprise or consist of an intact IgG molecule, or a variant thereof. The IgG molecule can be of any of the known subtypes, e.g., IgG1, IgG2, IgG3, or IgG4.
[0222] According to a specific embodiment, the antibody of the present invention comprises an h11B6 antibody that is an IgG1 antibody. According to a specific embodiment, the antibody of the present invention comprises an h11B6 antibody that is an IgG1 kappa isotype. According to a specific embodiment, the antibody of the present invention comprises an h11B6 antibody that is an IgG1 antibody or a variant thereof (e.g., an Fc variant).
[0223] In any of the embodiments disclosed herein (for brevity, hereinafter referred to as "in any embodiment disclosed herein" etc.), the antibody is selected from the group consisting of belimumab, mogamulizumab, blinatumomab, ibritumomab tiuxetan, obinutuzumab, ofatumumab, rituximab, inotuzumab ozogamicin, moxetumomab pasudotox, brentuximab vedotin, daratumumab, ipilimumab, cetuximab, necitumumab, panitumumab, dinutuximab, pertuzumab, These may include, but are not limited to, mab, trastuzumab, trastuzumab emtansine, siltuximab, cemiplimab, nivolumab, pembrolizumab, olaratumab, atezolizumab, avelumab, durvalumab, capromab pendetide, elotuzumab, denosumab, zib-aflibercept, bevacizumab, ramucirumab, tositumomab, gemtuzumab ozogamicin, alemtuzumab, cixutumumab, girentuximab, nimotuzumab, catumaxomab, or etaracizumab. In any of the embodiments disclosed herein, the antibody fragment is selected from the group consisting of belimumab, mogamulizumab, blinatumomab, ibritumomab tiuxetan, obinutuzumab, ofatumumab, rituximab, inotuzumab ozogamicin, moxetumomab pasudotox, brentuximab vedotin, daratumumab, ipilimumab, cetuximab, necitumumab, panitumumab, dinutuximab, pertuzumab, trastuzumab, trastuzumab emtansine, and the like. In some embodiments, the binding peptide may include, but is not limited to, a prostate-specific membrane antigen ("PSMA") binding peptide, a somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding compound, or a binding fragment thereof.
[0224] The immunoconjugates and radioimmunoconjugates of the invention can be prepared by any method known in the art, including chemical and / or enzymatic methods, in view of the present disclosure for conjugating a ligand (e.g., an antibody) to a compound of the invention. For example, the immunoconjugates and radioimmunoconjugates can be prepared by conjugation reactions, including, but not limited to, formation of esters, thioesters, or amides from activated acids or acyl halides; nucleophilic substitution reactions (e.g., nucleophilic substitution of a ring halide or ring opening of a ring system with strain); azide-alkyne Huisgen cycloaddition (e.g., 1,3 dipolar cycloaddition between an azide and an alkyne to form a 1,2,3-triazole linker); thiophosphorus addition reactions; imine formation; Diels-Alder reaction between tetrazine and trans-cycloctene (TCO); and Michael addition (e.g., maleimide addition). Many other addition modes with different linkages are possible, depending on the reactive functional groups used. Binding of the ligand can be to a compound that is coordinated to a radioactive metal ion or to a compound that is not coordinated to a radioactive metal ion.
[0225] In one embodiment, radioimmunoconjugates can be generated by covalently attaching a radiometal complex of the invention to an antibody or antigen-binding fragment thereof, for example by a click chemistry reaction (see, e.g., Figures 2B and 2D, referred to as "click radiolabeling"). Alternatively, radioimmunoconjugates can be generated by first preparing an immunoconjugate of the invention by covalently attaching a compound of the invention to an antibody or antigen-binding fragment thereof, for example by a click chemistry reaction, and subsequently labeling the immunoconjugate with a radiometal ion to generate the radioimmunoconjugate (see, e.g., Figures 2A and 2C, referred to as "one-step direct radiolabeling"). Both residue-specific (e.g., Figures 2A and 2B) and site-specific (e.g., Figures 2C and 2D) methods of conjugation can be used to generate the immunoconjugates and radioimmunoconjugates of the invention.
[0226] Residue-specific methods for conjugation to proteins are well established, most commonly involving either lysine side chains using activated esters or isothiocyanates, or cysteine side chains with maleimides, haloacetyl derivatives, or activated disulfides (Brinkley Bioconjugate Chem 1992:2). Because most proteins have multiple lysine and cysteine residues, heterogeneous mixtures of products with different numbers of conjugate molecules at various amino acid positions are typically obtained using such methods. Additional methods have been established, including tyrosine-specific conjugation (Ban et al. Bioconjugate Chemistry 2013:520), methionine-specific methods (Lin et al. Science 2017(355)597), and approaches focused on additional cysteines (Toda et al. Angew Chemie 2013:12592).
[0227] More recently, site-selective and site-specific conjugation methods have been established for monoclonal antibodies and other proteins (Agarwal, P. and C.R. Bertozzi, Bioconjug Chem, 2015.26(2):p.176-92; Rabuka et al. Curr Opin Chem Biol 2010:790). These include the incorporation of unnatural amino acids; fusion of the protein of interest to a "self-labeling tag" such as SNAP or DHFR or a tag that is specifically recognized and modified by another enzyme such as sortase A, lipoic acid ligase and formylglycine generating enzyme; enzymatic modification of glycans to allow conjugation of a payload of interest (Hu et al. Chem Soc Rev 2016:1691); the use of microbial transglutaminase to selectively recognize defined locations on antibodies; and additional methods that use molecular recognition and / or chemical approaches to affect selective conjugation (Yamada et al. 2019:5592; Park et al. Bioconjugate Chem 2018:3240; Pham et al. Chembiochem 2018:799).
[0228] In certain embodiments, the immunoconjugates or radioimmunoconjugates of the invention are generated using residue-specific methods for conjugating the compounds of the invention to antibodies or antigen-binding fragments thereof. Such residue-specific methods typically result in immunoconjugates or radioimmunoconjugates that are covalently linked to the compounds or radiometal complexes of the invention at various positions on the antibody. Any residue-specific method for forming protein or antibody conjugates known to those of skill in the art in view of the present disclosure can be used. Examples of residue-specific methods for conjugation that can be used include, but are not limited to, conjugating the compounds or radiometal complexes of the invention to lysine residues of antibodies, for example using compounds or radiometal complexes of the invention that contain activated ester or isothiocyanate groups, conjugating to cysteine residues of antibodies, for example using compounds or radiometal complexes of the invention that contain maleimides, haloacetyl derivatives, acyl halides, activated disulfide groups or methylsulfonylphenyloxadiazole groups, conjugating to tyrosine residues of antibodies, for example using compounds or radiometal complexes of the invention that contain 4-phenyl-3H-1,2,4-triazoline-3,5-(4H)-dione (PTAD), and conjugating to methionine residues of antibodies, for example using compounds or radiometal complexes of the invention that contain oxaziridine derivatives. It is also possible to label the antibodies with biorthogonal reactive functional groups at specific residues using one or more of the above methods prior to conjugation to the compounds or radiometal complexes of the invention. For example, tyrosine residues can be site-specifically labeled at a biorthogonal reactive functional group using an oxaziridine derivative coupled to a biorthogonal reactive functional group, such as azide, alkynyl, or cycloalkynyl, and then an antibody containing the labeled tyrosine residue can be conjugated to a compound of the invention or a radiometal complex of the invention using a compound or radiometal complex of the invention having a compatible reactive functional group.
[0229] In certain embodiments, the immunoconjugates or radioimmunoconjugates of the invention can be generated using site-specific or site-selective methods for conjugating the compounds of the invention to an antibody or antigen-binding fragment thereof. In contrast to residue-specific methods, "site-specific" or "site-selective" methods typically result in immunoconjugates or radioimmunoconjugates covalently linked to the compounds or radiometal complexes of the invention at specific positions on the antibody. Any site-specific method for forming protein or antibody conjugates known to those of skill in the art in view of the present disclosure can be used. For example, a mutant aminoacyl-tRNA synthetase capable of selectively aminoacylating a tRNA with the unnatural amino acid of interest can be used to specifically incorporate an unnatural amino acid (e.g., an azido or alkynyl amino acid) into an antibody. A mutant acylated tRNA can then be used with an amber suppressor tRNA to site-specifically incorporate the unnatural amino acid into a protein in response to an amber nonsense codon. Antibodies that are specifically labeled by one or more of the above methods can then be conjugated to a compound of the invention or a radiometal complex of the invention bearing a compatible reactive functional group.
[0230] In a particular embodiment, the present invention is directed to a method for preparing a radioimmunoconjugate comprising reacting a compound of the present invention, where R4 is a nucleophilic or electrophilic moiety, or a radiocomplex of the present invention, with an antibody or antigen-binding fragment thereof, or a modified antibody or antigen-binding fragment thereof comprising a nucleophilic or electrophilic moiety.
[0231] In one embodiment, the present invention is directed to a method comprising reacting a compound of the present invention with an antibody or antigen-binding fragment thereof, or a modified antibody or antigen-binding fragment thereof comprising a nucleophilic or electrophilic functional group to form an immunoconjugate having a covalent bond between the compound of the present invention and the antibody or antigen-binding fragment thereof, or the modified antibody or antigen-binding fragment, and reacting the immunoconjugate with a radioactive metal ion such that the radioactive metal ion is attached to the compound of the present invention of the immunoconjugate by a coordinate bond, thereby forming a radioimmunoconjugate. This embodiment may be referred to as a "one-step direct radiolabeling" method (e.g., as shown diagrammatically in FIG. 2C) since there is only one chemical reaction step involving a radioactive metal.
[0232] In another embodiment, the present invention is directed to a method comprising reacting a radioactive complex of the present invention with an antibody or antigen-binding fragment thereof, or a modified antibody or antigen-binding fragment thereof comprising a nucleophilic or electrophilic functional group, thereby forming a radioimmunoconjugate. This embodiment may be referred to as a "click radiolabeling" method (e.g., as shown diagrammatically in FIG. 2D). The modified antibody or antigen-binding fragment thereof may be generated by any method known in the art in view of the present disclosure, for example, by labeling the antibody with an orthogonally reactive functional group at a specific residue using one or more of the methods described above, or by site-specifically incorporating an unnatural amino acid (e.g., an azido or alkynyl amino acid) into the antibody using one or more of the methods described above. The degree of labeling (DOL), sometimes referred to as the degree of substitution (DOS), is a particularly useful parameter for characterizing and optimizing bioconjugates such as antibodies modified with unnatural amino acids. It is expressed as the average number of unnatural amino acids attached to a protein molecule (such as an antibody) or as a molar ratio in the form of label / protein. The DOL can be determined from the absorption spectrum of the labeled antibody by any method known in the art.
[0233] In certain embodiments of the present invention, the immunoconjugates and radioimmunoconjugates of the present invention are prepared using click chemistry reactions. For example, the radioimmunoconjugates of the present invention can be prepared using click chemistry reactions referred to as "click radiolabeling" (see, for example, Figures 2B and 2D). Click radiolabeling uses click chemistry reaction partners, preferably azides and alkynes (e.g., cyclooctyne or cyclooctyne derivatives), to form a triazole covalent bond between a radiocomplex (a radioactive metal ion bound to a compound of the present invention) and an antibody or an antigen-binding fragment thereof. Methods for click radiolabeling of antibodies are described, for example, in International Application No. US18 / 65913, entitled "Radiolabeling of Polypeptides," the relevant description of which is incorporated herein by reference. In other embodiments, referred to as "one-step direct radiolabeling," an immunoconjugate is prepared using a click chemistry reaction between an antibody or antigen-binding fragment thereof and a compound of the invention, and the immunoconjugate is then contacted with a radioactive metal ion to form a radioimmunoconjugate (see, e.g., Figures 2A and 2C).
[0234] In one embodiment, the present invention is directed to a method of preparing a radioimmunoconjugate comprising binding (eg, by coordinating) a radioactive metal ion to a compound of the present invention.
[0235] In one embodiment, the "one-step direct radiolabeling" method of preparing a radioimmunoconjugate comprises contacting an immunoconjugate (i.e., a polypeptide-compound of the invention complex) with a radioactive metal ion, thereby forming a radioimmunoconjugate, which comprises a compound of the invention. According to certain embodiments, the immunoconjugate is formed by a click chemistry reaction between a compound of the invention and a polypeptide. According to certain embodiments, the radioimmunoconjugate is formed without metal-free conditions (e.g., without any step of removing or actively eliminating common metal impurities from the reaction mixture). This is in contrast to certain conventional methods that require radiolabeling of antibodies under strict metal-free conditions to avoid competitive (non-productive) chelation of common metals such as iron, zinc and copper, which poses significant challenges to the manufacturing process.
[0236] In one embodiment, the present invention is directed to a method for preparing a radioimmunoconjugate (including a "one-step direct radiolabeling" method), comprising: (i) reacting a modified polypeptide with a compound of the invention, the modified polypeptide being an antibody or antigen-binding fragment thereof comprising an azide group, thereby obtaining an immunoconjugate; (ii) reacting the immunoconjugate with a radioactive metal ion to obtain a radioactive immunoconjugate.
[0237] In another embodiment, the present invention is directed to a method for preparing a radioimmunoconjugate (including a "one-step direct radiolabeling" method), comprising: (i) reacting a modified antibody or antigen-binding fragment thereof comprising an azide group with a compound of formula I to obtain an immunoconjugate; (ii) reacting the immunoconjugate with a radioactive metal ion to obtain a radioactive immunoconjugate.
[0238] In certain embodiments, the present invention is directed to a method of preparing a radioimmunoconjugate (including, for example, a "click radiolabeling" method as shown in FIG. 2D), comprising: (i) reacting the modified antibody or antigen-binding fragment thereof with a radioactive complex under conditions in which the azido group reacts with the alkynyl or cycloalkynyl group, thereby obtaining a radioimmunoconjugate.
[0239] Conditions for carrying out click chemistry reactions are known in the art, and any conditions for carrying out click chemistry reactions known to one of skill in the art in light of the present disclosure can be used in the present invention. Exemplary conditions include, but are not limited to, incubating the modified polypeptide and radioactive complex in a ratio of 1:1 to 1000:1 at a pH of 4 to 10 and a temperature of 20° C. to 70° C.
[0240] The above click radiolabeling methods allow complexation of radioactive metal ions under low or high pH and / or high temperature conditions to maximize efficiency, which can be achieved without the risk of inactivating the alkyne reaction partner. Efficient complexation between azide-labeled antibodies or antigen-binding fragments thereof and radioactive complexes and efficient SPAAC reactions allow the generation of radioactive immunoconjugates with high radiochemical yields even at low azide:antibody ratios. The only step that must exclude trace metals is the radioactive metal ion complexation to the macrocycle moiety, and the antibody production, purification, and conjugation steps do not need to be performed under metal-free conditions.
[0241] The compounds and radiometal complexes of the present invention can also be used to generate site-specific radiolabeled polypeptides (e.g., antibodies). The click radiolabeling method described herein utilizes established methods for site-specific introduction of azide groups onto antibodies, facilitating the site-specific generation of radioimmunoconjugates (Li, X., et al. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl, 2014. 53(28): p. 7179-82; Xiao, H., et al., Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew Chem Int Ed Engl, 2013. 52(52): p. 14080-3). Methods for attaching molecules to proteins or antibodies in a site-specific manner are known in the art, and any method of site-specific labeling of antibodies known to one of skill in the art can be used in the present invention in light of the present disclosure. Examples of methods for site-specific modification of antibodies suitable for use in the present invention include, but are not limited to, the incorporation of modified cysteine residues (e.g., THIOMAB™), the use of unnatural amino acids or glycans (e.g., selenocysteine, p-AcPhe, formylglycine generating enzyme (FGE, SMARTag™), etc.), and enzymatic methods (e.g., glycotransferases, endoglycosidases, microbial or bacterial transglutaminases (MTG or BTG), sortase A, etc.).
[0242] In a particular embodiment, modified antibodies or antigen-binding fragments thereof for use in generating immunoconjugates or radioimmunoconjugates of the invention can be obtained by trimming the antibody or antigen-binding fragment thereof with a bacterial endoglycosidase specific for β-1,4 linkages between core GlcNAc residues at the Fc-glycosylation site of the antibody, e.g., GlycINATOR (Genovis), which leaves the innermost GlcNAc on the Fc intact and allows site-specific incorporation of an azido sugar at that site. The truncated antibody or antigen-binding fragment thereof can then be reacted with an azido-labeled sugar, such as UDP-N-azidoacetylgalactosamine (UDP-GalNAz) or UDP-6-azido6-deoxyGalNAc, in the presence of a glycosyltransferase, such as GalT galactosyltransferase or GalNAc transferase, thereby obtaining the modified antibody or antigen-binding fragment thereof.
[0243] In other embodiments, modified antibodies or antigen-binding fragments thereof for use in producing immunoconjugates or radioimmunoconjugates of the invention can be obtained by deglycosylating the antibody or antigen-binding fragment thereof with an amidase, and then reacting the resulting deglycosylated antibody or antigen-binding fragment thereof with an azidoamine, preferably 3-azidopropylamine, 6-azidohexylamine or any azidolinker amine or any azidoalkyl / heteroalkylamine, such as azido-polyethylene glycol (PEG)-amines, such as O-(2-aminoethyl)-O'-(2-azidoethyl)tetraethylene glycol, O-(2-aminoethyl)-O'-(2-azidoethyl)pentaethylene glycol, O-(2-aminoethyl)-O'-(2-azidoethyl)triethylene glycol, or in the presence of microbial transglutaminase, to obtain the modified antibody or antigen-binding fragment thereof.
[0244] Any of the radiometal complexes described herein can be used to generate the radioimmunoconjugates of the invention. In certain embodiments, the radiometal complex has the formula (IM + ) structure.
[0245] In certain embodiments, the radioimmunoconjugate is any one or more structures independently selected from the group consisting of:
[0246] [ka] During the ceremony, M + is a radioactive metal ion, M + Actinium 225 ( 225 Ac), Radium 223 ( 233 Ra), Bismuth 213 ( 213 Bi), Pb-212( 212 Pb(II) and / or 212 Pb(IV)), Terbium-149( 149 Tb), Terbium-152 ( 152 Tb), Terbium 155 ( 155 Tb), Fermium 255 ( 255 Fm), Thorium 227 ( 227 Th), Thorium 226 ( 226 Th 4+ ), Astatine 211( 211 At), Cerium-134 ( 134 Ce), Neodymium 144 ( 144 Nd), Lanthanum 132 ( 132 La), Lantern 135 ( 135 La), and Uranium-230 ( 230 U) selected from the group consisting of L1 is absent or is a linker, mAb is an antibody or an antigen-binding fragment thereof; a radioimmunoconjugate.
[0247] In another embodiment, the radioimmunoconjugate is any one or more selected from the group consisting of:
[0248] [ka] wherein mAb is an antibody or an antigen-binding fragment thereof.
[0249] It should be noted that in the radioimmunoconjugate structures shown herein that include a "mAb," the structures do not show the residues of the mAb that bind to the radiometal complex (e.g., lysine residues of the mAb).
[0250] One embodiment of the present invention provides a radioimmunoconjugate having the structure:
[0251] [ka] (also referred to herein as TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate), In the formula, M + Actinium 225 ( 225 Ac), The mAb has binding specificity for hK2, e.g. (i) the mAb is an h11B6 antibody comprising a heavy chain (HC) variable region comprising the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and a light chain (LC) variable region comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16; and / or (ii) the mAb comprises a heavy chain variable region (VH) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17, and / or a light chain variable region (VL) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18.
[0252] One embodiment of the present invention provides a radioimmunoconjugate having the structure:
[0253] [ka] (i) the mAb is an h11B6 antibody comprising a heavy chain (HC) variable region comprising the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, and a light chain (LC) variable region comprising the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16; and / or (ii) the mAb comprises a heavy chain variable region (VH) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17, and / or a light chain variable region (VL) having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18.
[0254] Radioimmunoconjugates produced by the methods described herein can be analyzed using methods known to those of skill in the art in light of the present disclosure. For example, LC / MS analysis can be used to determine the ratio of compound to labeled polypeptide, e.g., antibody or antigen-binding fragment thereof, analytical size-exclusion chromatography can be used to determine the oligomeric state of polypeptides and polypeptide conjugates, e.g., antibodies and antibody conjugates, radiochemical yield can be determined by instant thin layer chromatography (e.g., iTLC-SG), and radiochemical purity can be determined by size-exclusion HPLC. Exemplary methods are described herein, e.g., in the Examples below.
[0255] Pharmaceutical Compositions and Methods of Use In another embodiment, the present invention is directed to a pharmaceutical composition comprising a compound of the present invention, a radiometal complex, an immunoconjugate, or a radioimmunoconjugate of the present invention, and a pharma- ceutical composition may also include one or more pharma- ceutical acceptable carriers.
[0256] In one embodiment, the pharmaceutical composition comprises a compound of the invention and a pharma- ceutically acceptable carrier.
[0257] In one embodiment, the pharmaceutical composition comprises a radiometal complex of the present invention and a pharma- ceutically acceptable carrier.
[0258] In another embodiment, a pharmaceutical composition comprises an immunoconjugate of the invention and a pharma- ceutically acceptable carrier.
[0259] In another embodiment, the pharmaceutical composition comprises a radioimmunoconjugate of the present invention and a pharma- ceutically acceptable carrier.
[0260] As used herein, the term "carrier" refers to any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid-containing vesicle, microsphere, liposomal encapsulation, or other material known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient, or diluent will depend on the route of administration for a particular application. As used herein, the term "pharmaceutical acceptable carrier" refers to a non-toxic material that does not interfere with the efficacy of the composition according to the invention or the biological activity of the composition according to the invention. According to certain embodiments, any pharmaceutical acceptable carrier suitable for use in antibody-based or radiocomplex-based pharmaceutical compositions in light of the present disclosure can be used in the present invention.
[0261] According to certain embodiments, the compositions described herein are formulated to be suitable for the intended route of administration to a subject. For example, the compositions described herein can be formulated to be suitable for parenteral administration, such as intravenous, subcutaneous, intramuscular or intratumoral administration.
[0262] In certain embodiments, the present invention is directed to radiation therapy and methods of selectively targeting tumor cells to treat a tumor disease or disorder. Any of the radiocomplexes or radioimmunoconjugates described herein and pharmaceutical compositions thereof can be used in the methods of the invention.
[0263] A "neoplasm" is an abnormal mass of tissue that occurs when cells divide more than necessary or do not die when they should. Tumors can be benign (not cancer) or malignant (cancer). Neoplasm is also called tumor. A neoplastic disease or disorder is a disease or disorder associated with a tumor, such as cancer. Examples of neoplastic diseases or disorders include, but are not limited to, disseminated cancer and solid tumor cancer.
[0264] In certain embodiments, the present invention is directed to a method of treating prostate cancer (e.g., metastatic prostate cancer, or metastatic castration-resistant prostate cancer) in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of an immunoconjugate or radioimmunoconjugate described herein, the immunoconjugate or radioimmunoconjugate comprising a radiometal complex described herein conjugated to H11B6.
[0265] The embodiments of the present invention are particularly useful for treating patients diagnosed with prostate cancer, for example, patients with late-stage prostate cancer. According to one embodiment, the cancer is non-localized prostate cancer. According to another embodiment, the cancer is metastatic prostate cancer. According to another embodiment, the cancer is castration-resistant prostate cancer (CRPC). According to another embodiment, the cancer is metastatic castration-resistant prostate cancer (mCRPC). According to another embodiment, the cancer is mCRPC with adenocarcinoma.
[0266] Other examples of diseases that may be treated by the methods of the invention described herein or targeted for radiation therapy include, but are not limited to, hypertrophy, coronary artery disease, or vascular occlusive disease, diseases or disorders associated with infected cells, microorganisms, or viruses, or diseases or disorders associated with inflammatory cells, such as rheumatoid arthritis (RA).
[0267] In one embodiment, the present invention is directed to a method for selectively targeting tumor cells for radiation therapy, the method comprising administering to a subject a radioimmunoconjugate or pharmaceutical composition of the present invention.
[0268] In one embodiment, the present invention is directed to a method of treating a tumor disease or disorder, comprising administering to a subject in need of treatment a radioimmunoconjugate or pharmaceutical composition of the present invention to the subject.
[0269] In one embodiment, the present invention is directed to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a radioimmunoconjugate or pharmaceutical composition of the present invention.
[0270] The radioimmunoconjugate delivers radiation directly, e.g., to a cell targeted by a targeting ligand. Preferably, the radioimmunoconjugate is 225 When targeted, the alpha-emitting radioactive metal ion, e.g., 225 Alpha particles from Ac and its daughters are delivered to targeted cells and cause a cytotoxic effect on the cells, thereby selectively targeting tumor cells for radiation therapy and / or treatment of a neoplastic disease or disorder.
[0271] The present invention further includes a pre-targeting approach for selectively targeting tumor cells for radiation therapy and for treating tumor diseases or disorders. According to the pre-targeting approach, an azide-labeled antibody or antigen-binding fragment thereof is administered, binds to cells bearing the antibody's target antigen, and is removed from the circulation over time or with a removal agent. Then, a radioactive metal complex of the present invention, preferably a radioactive metal complex comprising a cyclooctyne or cyclooctyne derivative (e.g., DBCO), is administered to undergo a SPAAC reaction with the azide-labeled antibody bound to the target site, and the remaining unbound radioactive metal complex is rapidly removed from the circulation. This pre-targeting technique provides a method for enhancing radioactive metal ion localization at the target site in a subject.
[0272] In other embodiments, the modified polypeptide, e.g., an azide-labeled antibody or antigen-binding fragment thereof, and the radiometal complex of the present invention are administered in the same composition or in different compositions to a subject in need of targeted radiation therapy or treatment of a neoplastic disease or disorder.
[0273] As used herein, the term "therapeutically effective amount" refers to an amount of an active ingredient or component that elicits a desired biological or pharmacological response in a subject. A therapeutically effective amount can be determined empirically and in a routine manner for the described purpose. For example, an in vitro assay can be optionally used to help identify optimal dosage ranges. The selection of a specific effective dose can be determined (e.g., by clinical trials) by a person skilled in the art based on consideration of several factors, including the disease to be treated or prevented, the associated symptoms, the patient's weight, the patient's immune status, and other factors known to those skilled in the art. The exact dose to be used in the formulation also depends on the route of administration and the severity of the disease, and should be determined according to the physician's judgment and each patient's circumstances. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0274] As used herein, the terms "treat", "treating" and "treatment" are all intended to refer to the improvement or restoration of at least one measurable physical parameter associated with a disease, disorder or condition that may be discernible in a subject, but not necessarily discernible in the subject, for which administration of a radioactive metal ion may be beneficial, such as a neoplastic disease or disorder. The terms "treat", "treating" and "treatment" may also refer to causing regression of, preventing the progression of, or at least slowing the progression of, a disease, disorder or condition. In certain embodiments, "treat", "treating" and "treatment" refer to the amelioration, prevention of the development or onset, or shortening of the duration of one or more symptoms associated with a disease, disorder or condition that may be discernible in a subject, such as a neoplastic disease or disorder, for which administration of a radioactive metal ion may be beneficial. In certain embodiments, "treat", "treating" and "treatment" refer to the prevention of recurrence of a neoplastic disease, disorder or condition. In certain embodiments, "treatment", "treating" and "treatment" refer to increasing the survival rate of a subject with a neoplastic disease, disorder or condition. In certain embodiments, "treat", "treating" and "treatment" refer to the elimination of a neoplastic disease, disorder or condition in a subject.
[0275] In some embodiments, a therapeutically effective amount of a radioimmunoconjugate or pharmaceutical composition of the present invention is administered to a subject to treat a neoplastic disease or disorder in the subject, such as cancer.
[0276] In another embodiment of the present invention, the radioimmunoconjugates and pharmaceutical compositions of the present invention may be administered in combination with other agents effective in the treatment of tumor diseases or disorders.
[0277] In additional embodiments, the present invention is directed to the radioimmunoconjugates and pharmaceutical compositions described herein for use in selectively targeting tumor cells for radiation therapy and / or treatment of a neoplastic disease or disorder, and to the use of the radioimmunoconjugates or pharmaceutical compositions described herein in the manufacture of a medicament for selectively targeting tumor cells for radiation therapy and / or treatment of a neoplastic disease or disorder.
[0278] Although certain embodiments have been illustrated and described, one of ordinary skill in the art, after reading the foregoing specification, may make modifications, equivalent substitutions, and other types of alterations to the compounds of the present technology described herein or their salts, pharmaceutical compositions, derivatives, prodrugs, metabolites, tautomers, or racemic mixtures. Each of the above aspects and embodiments may also include or incorporate the variations or aspects disclosed with respect to any or all of the other aspects and embodiments.
[0279] Numbered embodiments Exemplary numbered embodiments of the present invention are set forth below. 1. Compound 14 (6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid),
[0280] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0281] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof, to which a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent is added to obtain compound 10;
[0282] [ka] A process comprising the steps of reacting compound 10 under basic conditions in an organic solvent or a mixture thereof to obtain compound 13, and reacting compound 13 with thiocarbonyldiimidazole in an organic solvent or a mixture thereof to obtain compound 14. 2. Compound 14 (6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid)
[0283] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0284] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10;
[0285] [ka] 1. A process comprising the steps of: reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 13; and reacting compound 13 with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14. 3. Compound 14 (6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid)
[0286] [ka] A process according to embodiment 1 or 2 for the preparation of N-(N-(CH3)-COOH)-N,N-dimethylformamide (DMSO) or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0287] [ka] reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof to obtain compound 2;
[0288] [ka] reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof to obtain compound 3;
[0289] [ka] reacting 3 with 2 in an organic solvent or mixture thereof to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate);
[0290] [ka] reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 under reducing conditions in an organic solvent or mixture thereof to give compound 7;
[0291] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate);
[0292] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate to obtain compound 9;
[0293] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof, to which a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent is added to obtain compound 10;
[0294] [ka] A process comprising the steps of reacting compound 10 under basic conditions in an organic solvent or a mixture thereof to obtain compound 13, and reacting compound 13 with thiocarbonyldiimidazole in an organic solvent or a mixture thereof to obtain compound 14. 4. Compound 14 (6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid)
[0295] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0296] [ka] reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof at a temperature ranging from ambient temperature to −78° C. to obtain compound 2;
[0297] [ka] reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 3;
[0298] [ka] reacting 3 with 2 in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate);
[0299] [ka] reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 in an organic solvent or mixture thereof under reducing conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 7;
[0300] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate);
[0301] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 9;
[0302] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10;
[0303] [ka] reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 13, which is reacted with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14. 5. Compound 14
[0304] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0305] [ka] reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof at a temperature ranging from ambient temperature to −78° C. to obtain compound 2;
[0306] [ka] reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 3;
[0307] [ka] reacting 3 with 2 in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate);
[0308] [ka] reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 in an organic solvent or mixture thereof under reducing conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 7;
[0309] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate);
[0310] [ka] reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 9;
[0311] [ka] reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10;
[0312] [ka] reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 13, which is reacted with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14. 6. Compound 10
[0313] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0314] [ka] A process comprising reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof, and adding a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10. 7. Compound 10
[0315] [ka] or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0316] [ka] A process comprising reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., and adding a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10. 8. Compound 10
[0317] [ka] A process according to embodiment 6 or embodiment 7 for the preparation of N-(N-(CH3)-COOH)-N,N-dimethylformamide (DMSO) or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of:
[0318] [ka] 1. A process comprising reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., stirring for 5 to 60 minutes, and reacting the same with trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 10. 9. A process for preparing compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt), comprising:
[0319] [ka] The process is as follows: A process comprising the steps of reacting compound 10 (having a structure as described herein) with sodium hydroxide in an organic solvent or mixture thereof to obtain compound 11 (having a structure as described herein), and reacting compound 11 with thiocarbonyldiimidazole in an organic solvent or mixture thereof to obtain compound 12. 10. The process according to embodiment 9 for the preparation of compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt),
[0320] [ka] The process is as follows:
[0321] [ka] reacting compound 10 with sodium hydroxide in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 11;
[0322] [ka] reacting compound 11 with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 12. 11. The process according to embodiment 10 for the preparation of a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate, comprising:
[0323] [ka] A process comprising reacting an 8-fold to 12-fold excess of compound 12 (e.g., a 10-fold excess of compound 12) with h11b6 mAb and removing excess free chelating agent to obtain a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate. 12. The process according to embodiment 10 or embodiment 11 for the preparation of a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate, comprising:
[0324] [ka] A process comprising reacting an 8-12-fold excess of compound 12 (e.g., a 10-fold excess of compound 12) with h11b6mAb in a buffer adjusted to a pH of about 8-10 (e.g., a pH of about 9) and incubating at room temperature, and removing excess free chelating agent by desalting the reaction to obtain a TOPA-[C7]-phenylthiourea-h11b6 antibody conjugate. 13. A process according to any one of embodiments 10 to 12 for the preparation of a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate, comprising:
[0325] [ka] A process comprising reacting about a 10-fold excess of compound 12 with h11b6mAb in a pH about 5.2 buffer of 10 mM sodium acetate adjusted to a pH of about 9 with sodium bicarbonate buffer and incubating at room temperature for about 1 hour without shaking, quenching by adding 1 M Tris, pH about 8.5 to a final concentration of about 100 mM, removing excess free chelator by desalting the reaction into 10 mM sodium acetate, pH about 5.2, and removing excess chelator to obtain a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate. 14. A process according to any one of embodiments 10 to 13 for the preparation of a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate, comprising:
[0326] [ka] 2. A process comprising reacting a 10-fold excess of compound 12 with h11b6mAb in 10 mM sodium acetate pH about 5.2 buffer immediately adjusted to a pH of about 9 with sodium bicarbonate buffer and incubating at room temperature for about 1 hour without shaking; quenching by adding 1 M Tris, pH 8.5 to a final concentration of 100 mM; removing excess free chelator by desalting the reaction into 10 mM sodium acetate, pH 5.2 using a 7K Zeba desalting column; removing excess chelator by 3x sample dilution to 15 mL followed by concentration to 1 ml using a 50,000 MWCO Amicon concentrator before adjusting the sample to its final concentration to obtain TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate. 15. The compound of formula (12) (TOPA-[C7]-phenylisothiocyanate sodium salt).
[0327] [ka] 16. Compound of formula (14)
[0328] [ka] or a pharma- ceutically acceptable salt or solvate thereof. 17. A compound of formula (11).
[0329] [ka]
[0330] General synthesis scheme:
[0331] [ka]
[0332] Methods for the preparation of compound 2 are described in numerous publications, such as US Pat. No. 5,247,078. Justus Liebigs Annalen der Chemie (1977), (8), 1344-6; Syntheses(1990),68,227-33;Journal of Organic Chemistry(1987),52(23),5172-6;Russian Journal of General Chemistry(2010),80(5),1007-1010;Chinese Chemical Letters(1992),3(12),963-4;Journal of Organic Chemistry(1986),51(26),5373-84; and Journal of the Chemical Society, Chemical Communications (1991), (14), 956-7.
[0333] 4(A) Synthetic scheme for the preparation of compound.
[0334] [ka] During the ceremony, X is selected from the group consisting of Cl, Br, I, OSO2R', and P(O)(OR")2; R is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols; R' is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols; R' is selected from the group consisting of halogenated linear or branched chains of general formula (CY2)nCY3, where Y=F or Cl and n=0-8; R'' is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols.
[0335] The manufacturing process of compound 4(A) above is prepared as described above for compound 4, with modification of reaction conditions as necessary, as will be understood by those skilled in the art in light of this disclosure. These compounds are prepared by using a suitable solvent in the presence or absence of a base, and optionally in the presence of an additive. Solvents such as ACN, DMF, NMP, THF, MeTHF, dioxane, DMAc, DMSO, MeOH, EtOH, IPA, tert-BuOH, tert-AMOH, DCM, EtOAc, IPAc, or toluene. The base may be an inorganic base (e.g., Na2CO3, NaHCO3, K2CO3, KHCO3, CsCO3, KOH, NaOH, LiOH, K3PO4, K2HPO4, or KH2PO4), or an organic base (e.g., DBU, lutidine, PMP, DMAP, DCMA, DIPEA, or TEA). The additive may be NaCl, NaBr, NaI, KCl, KI, KBr, or CsCl.
[0336] 9(A) Synthetic scheme for the preparation of compound.
[0337] [ka] During the ceremony, X is selected from the group consisting of Cl, Br, I, OSO2R', and P(O)(OR")2; R is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols; R' is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols; R' is selected from the group consisting of halogenated linear or branched chains of general formula (CY2)nCY3, where Y=F or Cl and n=0-8; R'' is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols.
[0338] The manufacturing process of compound 9(A) above is prepared as described above for compound 9, with reaction conditions modified as necessary, as would be understood by one of skill in the art in light of this disclosure. The compound is prepared by using a suitable solvent in the presence of a base. Solvents such as ACN, DMF, NMP, THF, MeTHF, dioxane, DMAc, DMSO, MeOH, EtOH, IPA, tert-BuOH, tert-AMOH, DCM, EtOAc, IPAc, or toluene. The base may be an inorganic base (e.g., Na2CO3, NaHCO3, K2CO3, KHCO3, CsCO3, KOH, NaOH, LiOH, K3PO4, K2HPO4, or KH2PO4), or an organic base (e.g., DBU, lutidine, PMP, DMAP, DCMA, DIPEA, or TEA). The additive may be NaCl, NaBr, NaI, KCl, KI, KBr, or CsCl.
[0339] (A) Synthetic scheme for the preparation of compound 10.
[0340] [ka] During the ceremony, R is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols.
[0341] The process for making compound 10(A) above is prepared as described above for compound 10, with reaction conditions modified as necessary, as would be understood by one of skill in the art in light of this disclosure. The compound is prepared by using a suitable solvent in the presence of a base. Solvents such as ACN, DMF, NMP, THF, MeTHF, dioxane, DMAc, DMSO, MeOH, EtOH, IPA, tert-BuOH, tert-AMOH, DCM, EtOAc, IPAc, or toluene. The base may be an inorganic base (e.g., Na2CO3, NaHCO3, K2CO3, KHCO3, CsCO3, KOH, NaOH, LiOH, K3PO4, K2HPO4, or KH2PO4), or an organic base (e.g., DBU, lutidine, PMP, DMAP, DCMA, DIPEA, piperidine, or TEA). The acid may be HCl, TFA, MSA, phosphoric acid, KOAc / AcOH, TsCl-DMAP, BF3, OEt2, TMSI, TMSCl, or TMSOTf / BSA. Other reactants may be used, such as Pd / H2, Pt / H2, Pd(OH2) / H2, or CAN.
[0342] 13(A) Synthetic scheme for the preparation of compound.
[0343] [ka] During the ceremony, R is selected from the group consisting of primary straight or branched chain (C1-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, secondary straight or branched chain (C3-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols, and tertiary straight or branched chain (C4-C8) alkyl, alkenyl, alkynyl, aryl, or heteroaryl) alcohols.
[0344] The process for preparing compound 13(A) above is prepared as described above for compound 13, with reaction conditions modified as necessary, as would be understood by one of skill in the art in light of this disclosure. The compound is prepared by using a suitable solvent in the presence of a base and a suitable reagent. Solvents such as ACN, DMF, NMP, THF, MeTHF, dioxane, DMAc, DMSO, MeOH, EtOH, IPA, tert-BuOH, tert-AMOH, DCM, EtOAc, IPAc, or toluene. The base may be an inorganic base (e.g., Na2CO3, NaHCO3, K2CO3, KHCO3, CsCO3, KOH, NaOH, LiOH, K3PO4, K2HPO4, or KH2PO4), or an organic base (e.g., DBU, lutidine, PMP, DMAP, DCMA, DIPEA, piperidine, or TEA). The reagent may be Cl2CS, CS2, imidazole 2CS, NH2C(S)NH2, EtOC(S)SK, ClC(S)NMe2, Me2N(S)CSSC(S)NMe2, ClC(S)OR', R'OC(S), where R' = substituted and unsubstituted phenyl or heteroaryl groups.
[0345] 14(A) Synthetic scheme for the preparation of compound.
[0346] [ka] During the ceremony, Ra is selected from the group consisting of H, Na, K, Cs, Li, and amine salts, the amine salts being selected from the group consisting of pyridine, HNR', HNR'2, and NR'3; R' is selected from the group consisting of straight chain, branched chain, cyclic (substituted or unsubstituted) alkyl, alkenyl, alkynyl, aryl, and heteroaryl groups (C1-C8).
[0347] In one embodiment, R' is selected from the group consisting of bases containing one or more cyclic structures, with or without heteroatoms (examples are shown below).
[0348] [ka] During the ceremony, W is selected from the group consisting of O, NR, S, S(O), SO2, S(O)NH, S(O)NR', and SN(R')N(R'2), where R' is as defined above.
[0349] The process for preparing compound 14(A) above is prepared as described above for compound 14, with reaction conditions modified as necessary, as would be understood by one of skill in the art in light of this disclosure. The compound is prepared by using a suitable solvent in the presence of a base and a suitable reagent. Solvents such as ACN, DMF, NMP, THF, MeTHF, dioxane, DMAc, DMSO, MeOH, EtOH, IPA, tert-BuOH, tert-AMOH, DCM, EtOAc, IPAc, or toluene. The base may be an inorganic base (e.g., Na2CO3, NaHCO3, K2CO3, KHCO3, CsCO3, KOH, NaOH, LiOH, K3PO4, K2HPO4, or KH2PO4). EXAMPLES
[0350] The following examples are provided to aid in the understanding of the present invention and are not intended, and should not be construed, as in any way limiting the invention described in the claims appended hereto.
[0351] In the examples below, synthesis products are listed that were isolated as a residue. Those skilled in the art will understand that the term "residue" is not intended to be limiting of the physical state in which the product is isolated, and may include, for example, solids, oils, foams, gums, syrups, etc.
[0352] Abbreviations used herein, particularly in the Schemes and Examples, are as listed in Table A below.
[0353] [Table 1-1]
[0354] [Table 1-2]
[0355] As used herein, ambient temperature refers to room temperature, which typically ranges from about 20 to about 25°C (about 68 to about 77°F), or about 25°C.
[0356] As used herein, unless otherwise specified, the term "isolated form" is intended to mean that the compound exists in a form separated from any solid mixture with other compounds, solvent systems, or biological environments. In one embodiment of the present invention, any of the compounds described herein exists in isolated form.
[0357] As used herein, unless otherwise specified, the term "substantially pure form" shall mean that the molar percentage of impurities in the isolated compound is less than about 5 molar percent, preferably less than about 2 molar percent, more preferably less than about 0.5 molar percent, and most preferably less than about 0.1 molar percent. In one embodiment of the present invention, the compound of formula (I) is present in a substantially pure form.
[0358] As used herein, unless otherwise specified, the term "substantially free of corresponding salt forms" when used to describe a compound of formula (I) means that the mole percent of the corresponding salt form in the isolated base of formula (I) is less than about 5 mole percent, preferably less than about 2 mole percent, more preferably less than about 0.5 mole percent, and most preferably less than about 0.1 mole percent. In one embodiment of the present invention, the compound of formula (I) is present in a form that is substantially free of the corresponding salt form.
[0359] Example 1 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (TOPA-[C-7]-phenyl-carboxylic acid)
[0360] [ka]
[0361] Scheme 1
[0362] [ka]
[0363] Step 1: To a mixture of methyl 6-formylpicolinate (4.00 g, 24.2 mmol), (4-(tert-butoxycarbonyl)phenyl)boronic acid (10.7 g, 48.5 mmol), PdCl2 (0.21 g, 1.2 mmol), tri(naphthalen-1-yl)phosphine (0.50 g, 1.2 mmol) and potassium carbonate (10.0 g, 72.7 mmol) in a 500 mL three-neck round bottom flask under nitrogen at −78° C., tetrahydrofuran (100 mL) was added in one portion. The mixture was purged with nitrogen and stirred at room temperature for 30 min, then heated at 65° C. for 24 h. The reaction mixture was cooled to room temperature, filtered through a pad of Celite, and the filtrate was concentrated to dryness. The crude product was purified by silica gel chromatography (0-50% EtOAc / petroleum ether) to give methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate as a yellow oil (2.5 g, 30% yield).
[0364] Step 2: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate (2.50 g, 7.30 mmol), PPh3 (3.43 g, 13.1 mmol), N-bromosuccinimide (2.13 g, 12.0 mmol) and dichloromethane (30 mL) were added to a 250 mL three-neck round bottom flask at room temperature under nitrogen atmosphere and stirred for 1 h. The reaction solution was loaded onto a silica gel column and purified by chromatography (0-30% EtOAc / petroleum ether) to obtain the compound methyl 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate (1.65 g, 56% yield) as a yellow oil.
[0365] Step 3: A stir bar, methyl 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate (1.52 g, 3.69 mmol), methyl 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.50 g, 3.69 mmol), Na2CO3 (1.17 g, 11.1 mmol), and acetonitrile (30 mL) were added to a 250 mL three-neck round-bottom flask and the resulting heterogeneous mixture was heated at 90 °C under a nitrogen atmosphere for 16 h. The reaction mixture was then cooled to room temperature, filtered through a pad of Celite, and concentrated to dryness in vacuo to give the crude product. The crude product was purified by silica gel chromatography (0-10% MeOH / dichloromethane) to give methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate as a brown oil (1.2 g, 44%).
[0366] Step 4: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.2 g, 1.6 mmol), TFA (0.62 mL, 8.1 mmol) and DCM (20 mL) were added to a 100 mL three-neck round bottom flask at room temperature and stirred for 1 h. The reaction mixture was concentrated to dryness and the resulting crude product was purified by preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm; mobile phase: 0.1% TFA aqueous solution / ACN; flow rate: 15.0 mL / min) to give TOPA-[C-7]-phenyl-carboxylic acid (0.8 g, 72%) as a brown oil. LC-MS APCI:C 35 H 44 N4O 10 Calculated value 680.31; Observed value m / z [M+H] +681.5. Purity by LC-MS: 99.87%. Purity by HPLC: 97.14% (97.01% at 210 nm, 97.20% at 254 nm and 97.21% at 280 nm). Column: Atlantis dC18 (250×4.6 mm), 5 μm; Mobile phase A: 0.1% TFA in water, Mobile phase B: acetonitrile; Flow rate: 1.0 mL / min. 1 H NMR(400MHz,DMSO-d6):δ8.12-8.07(m,4H),8.00-7.98(m,2H),7.75-7.73(m,4H),6.10 (s,1H),4.67(s,2H),3.96(s,3H),3.91(s,3H),3.82(s,8H),3.56(s,8H),3.52(s,8H).
[0367] Example 2 6-((16-((6-carboxypyridin-2-yl)(4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid
[0368] [ka]
[0369] Scheme 2
[0370] [ka]
[0371] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.40 g, 0.60 mmol), tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (0.15 g, 0.60 mmol), triethylamine (0.18 g, 0.76 mmol), HATU (0.33 g, 0.90 mmol), and DCM (4.0 mL) were added to a 25 mL three-neck round bottom flask at 0° C. under nitrogen atmosphere. The mixture was stirred at room temperature overnight. The reaction was treated with water (10 mL) and extracted with dichloromethane (10 mL×3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give an oil, which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g).
[0372] Step 2: A stir bar, methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g, 0.20 mmol), MeOH (1.8 mL), and HCl in methanol (4 M, 1.0 mL, 4.0 mmol) were added to a 10 mL single-neck round-bottom flask at 0° C., then allowed to warm to room temperature and stirred for 2 h. The volatiles were removed in vacuo to give methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.15 g), which was used without purification.
[0373] Step 3: A stir bar, methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.12 mmol), triethylamine (37 mg, 0.37 mmol), dry DCM (2 mL), and carbon disulfide (14 mg, 0.18 mmol) were added to a pressure vial at room temperature under a nitrogen atmosphere. The vial was irradiated in a microwave at 90° C. for 30 minutes (power 150 W). The vial was then cooled to room temperature and the reaction mixture was diluted with dichloromethane (10 mL) and then washed successively with water (5 mL), 1 M HCl (5 mL), and water (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give methyl 6-((4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (100 mg), which was used without purification.
[0374] Step 4: A stir bar, methyl 6-((4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.12 mmol), and aqueous HCl (6N, 0.4 mL, 2.34 mmol) were added to a 10 mL one-neck round bottom flask and stirred at 50° C. for 3 h. The reaction mixture was cooled to room temperature and concentrated to dryness under vacuum to give an oil, which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm; mobile phase: 0.1% TFA in water / acetonitrile; flow rate: 15.0 mL / min) to give 6-((16-((6-carboxypyridin-2-yl)(4-((2-(2-(2-isothiocyanatoethoxy)ethoxy)ethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (5.0 mg). LC-MS APCI:C 40 H 52 NO 11 Calculated S: 824.34; Observed m / z [M+H] + 824.8. 1 H NMR(400MHz,CD3OD):δ8.22-8.20(m,2H),8.14-8.05(m,2H),7.94(d,J=8.00Hz,2H),7.79(d,J=8.00Hz,2H ),7.73-7.67(m,2H),6.16(s,1H),4.77(s,2H),3.93-4.00(m,8H),3.59-3.70(m,27H),3.47-3.44(m,2H).
[0375] Example 3 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid and
[0376] Example 4 6-((16-((6-carboxypyridin-2-yl)(4-((6-isothiocyanatohexyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid
[0377] [ka]
[0378] Scheme 3
[0379] [ka]
[0380] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.12 g, 0.18 mmol), tert-butyl(6-aminohexyl)carbamate (38 mg, 0.18 mmol), triethylamine (54 mg, 0.54 mmol), HATU (0.10 g, 0.27 mmol), and DCM (4.0 mL) were added to a 25 mL three-neck round bottom flask at 0° C. under nitrogen atmosphere. The reaction mixture was then warmed to room temperature and stirred overnight. The reaction mixture was then treated with water (10 mL) and extracted with dichloromethane (10 mL×3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give an oil which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((6-((tert-butoxycarbonyl)amino)hexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (70 mg) as a gummy oil.
[0381] Step 2: A stir bar, methyl 6-((4-((6-((tert-butoxycarbonyl)amino)hexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (70 mg, 0.080 mmol), MeOH (1.5 mL), and HCl in methanol (4 M, 0.4 mL, 1.6 mmol) were added to a 25 mL round bottom flask at 0° C., followed by bringing to room temperature and stirring for 2 h. The volatiles were removed in vacuo to give methyl 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (30 mg), which was used without purification.
[0382] Step 3: A stir bar, methyl 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (30 mg, 0.038 mmol), aqueous LiOH (1.1 mL, 0.1 N, 0.11 mmol), and MeOH (1.0 mL) were added to an 8 mL reaction vial and stirred at room temperature overnight. The reaction mixture was then treated with acetic acid to pH 6.5 and subsequently concentrated to dryness under vacuum at room temperature. The resulting product was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm; mobile phase: 10 mM aqueous ammonium acetate / ACN; flow rate: 15.0 mL / min) to give Example 3: 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (10 mg). LC-MS APCI:C 39 H 54 Calculated for N6O9: 750.40; Observed m / z [M+H] + 751.3. 1H NMR(400MHz,CD3OD):δ8.22(d,J=1.60Hz,2H),8.21-8.06(m,2H),7.92(d,J=8.40Hz,2H),7.80(d,J=8.40Hz,2H),7.75-7.69(m,2H),6.20(s ,1H),4.70(s,2H),4.02-3.92(m,8H),3.76-3.62(m,14H),3.51-3.32 (m,4H),2.93(t,J=8.00Hz,2H),1.67-1.64(m,4H),1.46-1.45(m,4H).
[0383] Step 4: A stir bar, methyl 6-((4-((6-aminohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.13 mmol), triethylamine (39 mg, 0.38 mmol), dry DCM (2 mL), and carbon disulfide (15 mg, 0.19 mmol) were added to a pressure vial under nitrogen atmosphere at room temperature. The vial was irradiated in a microwave at 90° C. for 30 minutes (power 150 W). The vial was then cooled to room temperature and the reaction mixture was diluted with dichloromethane (10 mL), washed with water (5 mL), 1 M HCl (5 mL), and water (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give methyl 6-((4-((6-isothiocyanatohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.1 g), which was used without purification.
[0384] Step 5: A stir bar, methyl 6-((4-((6-isothiocyanatohexyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.10 g, 0.12 mmol), and aqueous HCl (6N, 0.4 mL, 2.4 mmol) were added to a 10 mL round bottom flask and then stirred at 50° C. for 3 h. The reaction mixture was then cooled to room temperature and concentrated to dryness under vacuum to give a residue, which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 3.5 μm; mobile phase: 0.1% TFA in water / acetonitrile; flow rate: 2.0 mL / min) to give Example 4: 6-((16-((6-carboxypyridin-2-yl)(4-((6-isothiocyanatohexyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (15 mg). LC-MS APCI:C 40 H 52 Calculated for N6O9S: 792.35; Observed m / z [M+H] + 792.8. 1 H NMR(400MHz,CD3OD):δ8.23-8.20(m,2H),8.15-8.06(m,2H),7.92(d,J=8.40Hz,2H),7.79(d,J=8.40Hz,2H),7.74-7.68(m,2H) ),6.17(s,1H),4.77(s,2H),4.01-3.93(m,8H),3.75-3.56(m,16H),3.42-3.33(m,5H),1.74-1.64(m,4H),1.50-1.44(m,4H).
[0385] Example 5 6-((16-((6-carboxypyridin-2-yl)(4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid
[0386] [ka]
[0387] Scheme 4
[0388] [ka]
[0389] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.25 g, 0.37 mmol), 4-(2-aminoethyl)aniline (60 mg, 0.37 mmol), TEA (0.11 g, 0.15 mL, 1.1 mmol), HATU (0.21 g, 0.55 mmol), and DCM (5 mL) were added to a 25 mL three-neck round-bottom flask at 0° C. under nitrogen atmosphere. The reaction mixture was stirred at room temperature overnight, then water (10 ml) was added. The mixture was treated with 10% aqueous NaHCO3 (10 mL) and extracted with dichloromethane (10 mL x 3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give the product, which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((4-aminophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g).
[0390] Step 2: A stir bar, methyl 6-((4-((4-aminophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g, 0.15 mmol), TEA (45 mg, 65 μL, 0.45 mmol), DCM (3 mL), and CS2 (17 mg, 0.23 mmol) were added to a 10 mL microwave pressure vial at room temperature under nitrogen atmosphere. The reaction mixture was irradiated in a microwave (power 150 W) at 90 °C for 30 minutes. The reaction mixture was then cooled to room temperature, diluted with dichloromethane (10 mL), water (5 mL), 1 M Washing with HCl (5 mL) and water (5 mL), followed by drying over anhydrous Na2SO4, and concentration to dryness gave methyl 6-((4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g), which was used without purification.
[0391] Step 3: A stir bar, methyl 6-((4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.12 g, 0.14 mmol), and aqueous HCl (0.50 mL, 6N, 2.8 mmol) were added to a 10 mL one-neck round bottom flask and stirred at 50° C. for 3 h. The reaction mixture was cooled to room temperature, concentrated to dryness under vacuum, and the crude product was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm; mobile phase: 0.1% TFA in water / acetonitrile; flow rate: 15.0 mL / min) to give 6-((16-((6-carboxypyridin-2-yl)(4-((4-isothiocyanatophenethyl)carbamoyl)phenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (30 mg). LC-MS APCI:C 42 H48 N5O 10 Calculated S: 812.32; Observed m / z [M+H] + 812.9. 1 H NMR(400MHz,CD3OD):δ8.22(d,J=0.80Hz,2H),8.06-8.21(m,2H),7.85(d,J=8.40Hz,2H),7.68-7.78(m,4H),7.31(d,J=8.40Hz,2H) ),7.21(d,J=2.00Hz,2H),6.18(s,1H),4.77(s,2H),3.70-4.00(m,7H),3.60-3.67(m,16H),3.44-3.49(m,2H),2.90-3.10(m,3H).
[0392] Example 6 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid
[0393] [ka]
[0394] Scheme 9
[0395] [ka]
[0396] Step 1: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.40 g, 0.60 mmol), tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (0.15 g, 0.60 mmol), triethylamine (0.18 g, 0.76 mmol), HATU (0.33 g, 0.90 mmol), and DCM (4.0 mL) were added to a 25 mL three-neck round bottom flask at 0° C. under nitrogen atmosphere. The mixture was stirred at room temperature overnight, diluted with water (10 mL), and extracted with dichloromethane (10 mL×3). The combined extracts were washed with 10% aqueous NaHCO3 (10 mL), and brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give a concentrate which was purified by silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g).
[0397] Step 2: A stir bar, methyl 6-((4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.18 g, 0.20 mmol), MeOH (1.8 mL), and HCl in methanol (4 M, 1.0 mL, 4.0 mmol) were added to a 10 mL one-neck round bottom flask at 0° C., then brought to room temperature and stirred for 2 h. The volatiles were removed in vacuo to give methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.15 g), which was used without purification.
[0398] Step 3: A stir bar, methyl 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (0.1 g, 0.1 mmol), aqueous LiOH (3 mL, 0.1 N, 0.3 mmol), and MeOH (1.0 mL) were added to an 8 mL reaction vial at room temperature and stirred overnight. The reaction mixture was adjusted to pH 6.5 with acetic acid and then concentrated to dryness under vacuum at room temperature to give a concentrate, which was purified by preparative HPLC (column: XBRIDGE C18 19×150 mm, 5.0 μm; mobile phase: 0.1% TFA in water / ACN; flow rate: 15.0 mL / min) to give 6-((4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamoyl)phenyl)(16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (40 mg). LC-MS APCI:C 39 H 54 NO 11Calculated for; 782.39; Observed m / z [M+H]+ 783.0.
[0399] Example 7 N-Acyl-DBCO tagged 6-((4-((6-aminoethyl)carbamoyl)phenyl)16-((6-carboxypyridin-2-yl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (TOPA-[C7]-benzimide-DBCO)
[0400] [ka]
[0401] Scheme 15
[0402] [ka]
[0403] Step 1: To a mixture of methyl 6-formylpicolinate (4.00 g, 24.2 mmol), (4-(tert-butoxycarbonyl)phenyl)boronic acid (10.7 g, 48.5 mmol), PdCl2 (0.21 g, 1.2 mmol), tri(naphthalen-1-yl)phosphine (0.50 g, 1.2 mmol) and potassium carbonate (10.0 g, 72.7 mmol) in a 500 mL three-neck round bottom flask at −78° C. under nitrogen, tetrahydrofuran (100 mL) was added in one portion. The mixture was purged with nitrogen and stirred at room temperature for 30 min, then heated at 65° C. for 24 h. The reaction mixture was cooled to room temperature, filtered through a pad of Celite®, and the filtrate was concentrated to dryness. The crude product was subjected to silica gel chromatography (0-50% EtOAc / petroleum ether) to afford methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate (2.5 g, 30%) as a yellow oil.
[0404] Step 2: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(hydroxy)methyl)picolinate (2.50 g, 7.30 mmol), PPh3 (3.43 g, 13.1 mmol), N-bromosuccinimide (2.13 g, 12.0 mmol) and DCM (30 mL) were placed in a 250 mL three-neck round bottom flask at room temperature under nitrogen atmosphere and stirred for 1 h. The reaction solution was loaded onto a silica gel column and purified using 0-30% ethyl acetate in petroleum ether to obtain the compound methyl 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate (1.65 g, 56%) as a yellow oil.
[0405] Step 3: A stir bar, methyl 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.52 g, 3.69 mmol), 6-(bromo(4-(tert-butoxycarbonyl)phenyl)methyl)picolinate (1.50 g, 3.69 mmol), Na2CO3 (1.17 g, 11.1 mmol), and acetonitrile (30 mL) were added to a 250 mL three-neck round bottom flask and the resulting heterogeneous mixture was heated at 90° C. for 16 h under nitrogen atmosphere. The reaction mass was then cooled to room temperature, filtered through a pad of Celite®, and concentrated to dryness in vacuo to give the crude product. The crude product was subjected to silica gel chromatography (0-10% MeOH / DCM) to give methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.2 g, 44%) as a brown oil.
[0406] Step 4: A stir bar, methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (1.2 g, 1.6 mmol), TFA (0.62 mL, 8.1 mmol) and DCM (20 mL) were added to a 100 mL three-neck round bottom flask at room temperature and stirred for 1 h. The reaction mixture was concentrated to dryness, and the resulting crude product was subjected to preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm; mobile phase: 0.1% TFA aqueous solution / ACN; flow rate: 15.0 mL / min) to obtain 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.8 g, 72%) as a brown oil. LC-MS APCI:C 35 H 44 N4O 10 Calculated value 680.31; Observed value m / z [M+H] + 681.5. Purity by LC-MS: 99.87%. Purity by HPLC: 97.14% (97.01% at 210 nm, 97.20% at 254 nm, and 97.21% at 280 nm); Column: Atlantis dC18 (250×4.6 mm), 5 μm; Mobile phase A: 0.1% TFA in water, Mobile phase B: acetonitrile; Flow rate: 1.0 mL / min. 1 H NMR(400MHz,DMSO-d6):δ8.12-8.07(m,4H),8.00-7.98(m,2H),7.75-7.73(m,4H),6.10 (s,1H),4.67(s,2H),3.96(s,3H),3.91(s,3H),3.82(s,8H),3.56(s,8H),3.52(s,8H).
[0407] Step 5: A stir bar, 4-((6-(methoxycarbonyl)pyridin-2-yl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)benzoic acid (0.25 g, 0.37 mmol), DBCO (0.10 g, 0.37 mmol), triethylamine (0.16 mL, 1.1 mmol), HBTU (0.21 g, 0.55 mmol) and DCM (10 mL) were added to a 25 mL three-neck round bottom flask at room temperature under nitrogen atmosphere at 0° C. and stirred for 16 hours. The reaction was quenched with water (20 mL) and extracted with DCM (3×20 mL). The combined extracts were washed with 10% aqueous NaHCO3 (20 mL), brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness to give the crude product as an oil, which was subjected to silica gel chromatography (0-10% MeOH / DCM) to give TOPA dimethyl ester-[C7]-phenyl-DBCO (0.12 g, 35%) as a colorless gummy oil.
[0408] Step 6: A stir bar, TOPA dimethyl ester-[C7]-phenyl-DBCO (0.1 g, 0.1 mmol), aqueous LiOH·HO (3 mL, 0.1 N, 0.3 mmol), and THF / MeOH / HO (4:1:1 v / v / v, 2 mL) were added to an 8 mL reaction vial at room temperature and stirred for 2 h. The reaction mixture was neutralized with aqueous HCl (1 N) to pH 6.5. The reaction mixture was concentrated to dryness in vacuo at room temperature and the resulting crude product was subjected to preparative HPLC (column: XBRIDGE C18 (19×150 mm) 5.0 μm; mobile phase: 10 mM aqueous ammonium acetate / ACN; flow rate: 15.0 mL / min) to give TOPA-[C7]-phenyl-DBCO (20 mg, 21%) as an off-white solid. LC-MS APCI:C 51 H 54 NO 10 Calculated value 910.39; observed value m / z [MH] +909.3. Purity by LC-MS: 92.47%. Purity by HPLC: 90.68% (88.04% at 210 nm, 90.43% at 254 nm and 93.56% at 280 nm); Column: XBRIDGE C8 (50×4.6 mm), 3.5 μm; Mobile phase A: 10 mM ammonium bicarbonate in water, Mobile phase B: acetonitrile; Flow rate: 1.0 mL / min. 1 H NMR(400MHz,DMSO-d6):δ7.84-7.82(m,4H),7.60-7.29(m,12H),7.13-7.10(m,2H), 5.12-5.02(m,2H),3.97(s,2H),3.59-3.44(m,20H),2.85(s,4H),2.73-2.68(m,6H).
[0409] Example 8 TOPA-[C7]-Benzimide-DBCO-triazole-PSMB-127 antibody conjugate
[0410] [ka]
[0411] Step 1. Azide modification and click reaction of mAb: PSMB127 was site-selectively modified with 100-fold molar excess of 3-azidopropylamine and microbial transglutaminase (MTG; Activa TI) at 37°C. The addition of two azides on the heavy chain of the mAb was monitored by intact mass ESI-TOF LC-MS on an Agilent G224 instrument. Excess 3-azidopropylamine and MTG were removed and the azide-modified mAb (azido-mAb) was purified using a 1 mL GE Healthcare MabSelect column. The azido-mAb was eluted from the resin using 100 mM sodium citrate (pH 3.0) and then exchanged into 20 mM Hepes, 100 mM NaCl (pH 7.5) using a 7K Zeba® desalting column. A 10-fold molar excess of TOPA-[C7]-phenyl-DBCO was reacted with site-specific azide-PSMB127 (DOL=2) for 1 hour at 37° C. without shaking. The completion of the DBCO-azide click reaction was monitored by intact mass spectrometry. Excess free chelator was removed by desalting the conjugate into 20 mM Hepes, 100 mM NaCl, pH 7.5 on a Zeba® 7K desalting column, followed by three 15-fold serial dilution steps and concentration into 20 mM Hepes, 100 mM NaCl, pH 7.5 using a 30K MWCO Amicon concentrator device by spinning at 3800×g. This gave the final site-specific TOPA-[C7]-phenyl-DBCO-PSMB127 conjugate with CAR=2. The final conjugate was confirmed to be monomeric by analytical size exclusion chromatography using a Tosoh TSKgel G3000SWxl 7.8mm x 30cm, 5u column, column temperature: room temperature, column eluted with DPBS buffer (x1, calcium and magnesium free), flow rate: 0.7mL / min, 18min run, injection volume: 18μL.
[0412] Step 2. Chelation: Stock solutions of the following metal salts were prepared in pure water:
[0413] [Table 2]
[0414] The final conjugate was confirmed to be monomeric by analytical size-exclusion chromatography eluting with 10 mM sodium acetate at a 5-fold molar excess of the metal solution. It was added to TOPA-[C7]-phenyl-DBCO-PSMB127 (6.8 μM antibody, 34 μM metal ion) in 10 mM NaCl (pH 5.2) and incubated for 2 hours at 37° C. Excess metal was removed by desalting on a Zeba® column (ThermoFisher®) followed by two cycles of 10-fold dilution and concentration on a 50K MWCO Amicon concentrator (EMD Millipore®). Chelation was assessed by intact and reduced mass LC-MS.
[0415] Step 3. Stability determination: A DTPA challenge was performed to determine the stability of the chelate. 50 μL of sample (6.3 μM antibody) was combined with 50 μL of 10 mM DTPA (pH 6.5) and incubated overnight at 37° C. Chelation was assessed by intact and reduced mass LC-MS. LC-MS was performed on an Agilent 1260 HPLC system connected to an Agilent G6224 MS-TOF mass spectrometer. LC was run on an Agilent RP-mAb C4 column (2.1×50 mm, 3.5 microns) with a flow rate of 1 mL / min, mobile phases 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (Sigma-Aldrich catalogue no. 34688) (B), and a gradient of 20% B (0-2 min), 20-60% B (2-3 min), 60-80% B (3-5.5 min). The instrument was operated in positive electrospray ionization mode and scanned from m / z 600 to 6000. Mass-to-charge spectra were deconvoluted using a maximum entropy algorithm and the relative abundances of related species were estimated by the peak heights of the deconvoluted masses. Instrument settings included: capillary voltage 3500 V, fragmentor 175 V, skimmer 65 V; gas temperature 325 C, drying gas flow rate 5.0 L / min, nebulizer pressure 30 psig, acquisition mode range 100-7000 with a 0.42 scan rate.
[0416] A change in MW relative to TOPA-[C7]-phenyl-DBCO-PSMB127 was observed for the cerium and neodymium samples. The intact mass of the conjugate incubated with cerium showed an increase in MW of 139 Da (20% by peak area) or 276 Da (77%), corresponding to the addition of one or two cerium ions. After DTPA challenge, the masses remained similar, as did the abundances (30% and 67% for the +138 and +274 species).
[0417] Example 9 6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (H2bp18c6 benzyl-phenyl) (TOPA-[C7]-phenyl isothiocyanate and sodium salt forms
[0418] [ka]
[0419] Compound 2 was prepared in a similar manner to that described previously (see J. Org. Chem. 1987, 52, 5172).
[0420] [ka]
[0421] Compound 3 was prepared in a similar manner to the existing method (see Chemistry-a European Journal; 2015, 21, 10179.).
[0422] [ka]
[0423] Preparation of compound 4:
[0424] [ka]
[0425] 1,4,10,13-Tetraoxa-7,16-diazacyclooctadecane (494 g, 1.88 mol, 2.5 equiv), NaCl (44.1 g, 0.75 mol, 1.0 equiv), HO (140 mL, 1 volume relative to compound 3) and acetonitrile (2.1 L, 15 volumes) were charged to a 10 L reactor at 15-20 °C under N2 atmosphere and heated to 65 °C. To the resulting mixture was added a solution of compound 3 (140 g, 0.75 mol) in acetonitrile (280 mL, 2 volumes) dropwise over 1 h at 65 °C. This solution was aged at 65 °C for 0.5 h. LCMS analysis of the mixture indicated the reaction was complete. The mixture was allowed to cool to room temperature and concentrated under reduced pressure. Acetone (700 mL, 5 volumes) was added to the mixture and the suspension was stirred for an additional 1 h. The mixture was filtered (the filtered solid was unreacted compound 2). The filtrate was concentrated under vacuum and then dissolved in DCM (1.4 L, 10 vol). The organic phase was washed with water (3×750 mL) and the organic phase was dried over Na2SO4 and then concentrated under vacuum to give 212 g of compound 4 (63% yield, assay: 85% w / w). LCMS: (ES, m / z): 412.15 [M+H] +1 H-NMR(300MHz,DMSO-d6,ppm):δ7.98-7.87(m,2H),7.81(dd,J=6.4,2.6Hz,1H ),3.87(s,3H),3.81(s,2H),3.61-3.38(m,16H),2.77(dt,J=19.0,5.2Hz,8H).
[0426] Preparation of compound 7:
[0427] [ka]
[0428] Methyl 6-formylpicolinate 5 (250 g, 1.0 equiv.), (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 (538 g, 1.5 equiv.) and degassed THF (6.5 L, 26 volumes relative to 5) were charged to a 10 L reactor at 15-20 °C under N2 atmosphere. This was followed by the addition of PdCl2 (14.0 g, 0.05 equiv.), tri(naphthalen-1-yl)-phosphane (31 g, 0.05 equiv.) and K2CO3 (650 g, 3.1 equiv.). The resulting solution was stirred at 20 °C for 0.5 h. The mixture was then heated to 65 °C and aged for 17 h. Analysis by LCMS indicated the reaction was complete. The resulting solution was cooled to room temperature and diluted with ice water (2.5 L, 10 volumes) and ethyl acetate (5 L, 20 volumes). The mixture was filtered through a pad of Celite. The solution was separated and the lower aqueous layer was discarded. The organic phase was washed with water (2×1.5 L, 12 vol). The layers were separated and the organic layer was dried over Na2SO4 and concentrated under vacuum. The resulting residue was treated with heptane (1.25 L, 5 vol) and the resulting suspension was stirred for 0.5 h. The mixture was filtered and the filter cake was washed with n-heptane (500 mL, 2 vol) to give 530 g (98% yield, LCAP purity: 90%) of the desired product 7 as a yellow solid, which was used directly in the next step without further purification. LCMS: (ES, m / z): 381.10 [M+Na] +1 H-NMR(300MHz,DMSO-d6,ppm):δ9.27(s,1H),8.03-7.85(m,2H),7.79(dd,J=7.7,1.4Hz,1H),7.39(d,J=8 .4Hz,2H),7.26(d,J=8.4Hz,2H),6.13(d,J=4.0Hz,1H),5.72(d,J=3.9Hz,1H),3.87(s,3H),1.46(s,9H).
[0429] Preparation of compound 8:
[0430] [ka]
[0431] Methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 (310 g, 1.0 equiv), triethylamine (219 g, 2.5 equiv) and DCM (6.2 L, 20 volumes relative to 7) were charged to a 10 L reactor at 15-20° C. under nitrogen atmosphere and the solution was cooled to 0° C. Methanesulfonyl chloride (99.2 g, 1.0 equiv) was added dropwise over 30 min while maintaining the temperature at 0° C. The cooling bath was removed and the temperature was allowed to come to ambient temperature and aged at this temperature for 1 h. The solution was concentrated under vacuum at 10-15° C. and the residue was then dissolved in acetonitrile (438 mL, 2 volumes). The resulting solution was concentrated under vacuum to give 518 g (crude) of the desired product 8. The crude product was used directly in the next step without further purification.
[0432] Preparation of compound 9:
[0433] [ka]
[0434] Methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 (212 g, 1.0 equiv., 85% pure by Q-NMR), Na2CO3 (137.6 g, 3.0 equiv.), and acetonitrile (3.56 L, 20 volumes relative to 8) were charged into a 10 L reactor at room temperature under a nitrogen atmosphere, and the mixture was then cooled to 65° C. ℃The mixture was heated to rt and aged for 1 h. A solution of methyl 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 (377.8 g, 2.0 equiv.) in acetonitrile (3 L, 10 vol.) was added dropwise over 0.5 h at 65 °C. The mixture was aged at this temperature until HPLC analysis showed the reaction was complete. The resulting solution was cooled at room temperature and then filtered, and the filter cake was washed with MeOH (2 × 1 vol.). The filtrate was concentrated under vacuum and the resulting residue was dissolved in EA (700 mL), then silica gel (800 g, type: ZCX-2, 100-200 mesh, 2.11 w / w) was added. The mixture was concentrated under vacuum while maintaining the temperature below 35 °C. Silica gel (9.6 kg, type: ZCX-2, 100-200 mesh, 26.3 w / w) was packed into a column, followed by the prepared dried silica gel containing the adsorbed crude product 9. The column was eluted with ethyl acetate:petroleum ether;dichloromethane (3:3:1) / methanol:dichloromethane (1:1) (gradient from 100:0 to 90:10, sample collection every 4 L±0.5 L). Fractions were analyzed by TLC (ethyl acetate:ethyl acetate:petroleum ether;dichloromethane:methanol=4:4:1:1). The product-containing fractions were combined and concentrated to give 260 g of compound 9 as a yellow solid (HPLC: 94%, QNMR: 92%). An additional 70 g of compound 9 was obtained as a yellow oil (HPLC: 75%, QNMR: 60%). LCMS (ES, m / z): 752.30 [M+H] + Observed value m / z 1 H-NMR (400MHz, CDCl3, ppm): δ7.53-7.32(m,3H),7.28-7.18(m,3H),6.86(d,J=8.4Hz,2H),6.76(d,J=8.4Hz,2H),6.0 9(s,1H),4.63(s,1H),3.48(s,3H),3.44(bs,5H),3.17-2.92(m,16H),2.38(dq,J=25.0,7.2,6.8Hz,8H),0.97(s,9H).
[0435] Preparation of Compound 10:
[0436] [ka]
[0437] Compound 9 (260 g, QNMR: 92%, 1.0 equiv.), N,O-bis(trimethylsilyl)acetamide (BSA, 6.0 equiv.) and acetonitrile (4 L, 15 vol.) were placed in a 10 L reaction vessel at 15-20 °C under nitrogen atmosphere. The mixture was stirred at 20 °C for 40 min. A solution of TMSOTf (212.9 g, 3.0 equiv.) in acetonitrile (1.3 L, 5 vol.) was added dropwise over 0.5 h while maintaining the internal temperature at 15-20 °C. The resulting solution was aged at 15-20 °C for 1 h. When the in-process analysis (sample preparation: solution system 0.1 mL + ACN 0.9 mL + 1 drop diisopropylethylamine) showed complete conversion of the starting material, the mixture was quenched with diisopropylethylamine (617 g, 15.0 equiv.) while maintaining the temperature at 5-10 °C. The mixture was stirred at 5-10 °C for 20 min, then saturated aqueous NH4Cl (2.6 L, 10 vol) was charged while maintaining the temperature at 5-10 °C. The mixture was aged at this temperature for another 30 min. The aqueous phase (containing solids) was collected and extracted with 2-MeTHF (520 mL, 2 vol). The organic phases were combined, checked for water content by KF (KF: 9.18%), and then dried with anhydrous Na2SO4 (500 g, 10.0 equiv). The solids were removed by filtration and the filter cake was washed with acetonitrile (2 x 520 mL, 2 vol). The filtrate was then dried with anhydrous Na2SO4 (500 g, 10.0 equiv). After filtration, the filter cake was washed with acetonitrile (2 x 520 mL, 2 vol) and checked for water content by KF (KF: 8.15%). The acetonitrile / 2-MeTHF extract 10 was used directly in the next step. (The product was not stable to the LCMS conditions).
[0438] Preparation of compound 14 (free acid)
[0439] [ka]
[0440] Methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate (6.0 g, 1.0 equiv.) and BSA (9.7 g, 6.0 equiv.) and MeCN (120 mL, 20 vol. for 9) were charged to a 500 mL reaction vessel at room temperature under nitrogen atmosphere. A solution of TMSOTf (5.4 g, 2.3 equiv.) in MeCN (120 mL, 20 vol.) was added dropwise at room temperature over 30 min. The mixture was aged overnight at room temperature. Analysis of the mixture (sample preparation: solution system 0.1 mL + ACN 0.9 mL + 1 drop diisopropylethylamine) indicated that the reaction had reached completion. The mixture was quenched with diisopropylethylamine (15.4 g, 15.0 equiv.) and the temperature was maintained at 0-5 °C. The mixture was stirred at 0-5 °C for 5 min, then saturated NH4Cl solution (60 mL, 10 vol.) was added dropwise while maintaining the temperature at 0-5 °C. The aqueous phase was removed by extraction and the organic phase was collected and used directly in the next step. The organic phase was placed in a 500 mL three-necked round-bottom bottle and a solution of LiOH (1.15 g, 6.0 equiv.) in water (60 mL, 10 vol.) was added to the solution at room temperature. The solution was stirred at room temperature for 1 h. Analysis of the mixture (sample preparation: solution system 0.1 mL + acetonitrile 0.9 mL) showed no complete conversion. More LiOH (576 mg, 3.0 equiv.) was added and the solution was stirred at room temperature for another 1 h. Analysis of the mixture (sample preparation: solution system 0.1 mL + acetonitrile 0.9 mL) showed that the reaction had reached completion. Then TCDI (5.6 g, 3.9 equiv.) was added and the solution was stirred at room temperature for 1 h. Analysis of the mixture (sample preparation: 0.1 mL solution system + 0.9 mL acetonitrile) showed no complete conversion. Further TCDI (2.8 g, 2.0 equiv.) was added and the solution was stirred at room temperature for another 1 h. Analysis of the mixture (sample preparation: 0.1 mL solution system + 0.9 mL acetonitrile) showed that the reaction had reached completion. The reaction solution was separated by reversed phase Combi-Flash. Method: column C18, solution A H2O (containing 0.01% formic acid), solution B ACN. From 5% to 35% in 40 min, flow rate (100 mL / min), product 20 min to 25 min. The solution was collected.The solution was concentrated to remove ACN and separated again by reversed phase Combi-Flash. Method: column C18, A solution H2O, B solution ACN. 5% 10 min, 5%-35% in 5 min, 95% 10 min, flow rate (100 mL / min), product 13-25 min. Collect the solution. The solution was concentrated under reduced pressure below 20 °C and dried by lyophilization. This gave 2.5 g (47% yield over 3 steps) of compound 14 as a yellow solid. Compound 14 (6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid) had to be stored at -80 °C. LCMS: (ES, m / z): 666.3 [M+H]. +1 H-NMR:(400MHz,D2O,ppm):7.94-7.84(m,4H),7.56-7.40(m,4H),7.16-7.14(m,2H), 5.83(s,1H),4.56(s,2H),3.80-3.75(m,8H),3.60-3.49(m,14H),3.36-3.33(m,2H).
[0441] Preparation of compound 11 (sodium salt):
[0442] [ka]
[0443] The prepared solution of compound 10 in ACN and 2-MeTHF was placed in a 10 L four-necked reaction vessel and the solution was cooled to 5-10 °C. Powdered NaOH (56.9 g, 4.5 equiv.) was added while maintaining the temperature at 5-10 °C. The resulting solution was stirred at 15-20 °C for 0.5 h. Analysis of the mixture (sample preparation: 0.1 mL solution system + 0.9 mL acetonitrile) showed no conversion. Additional powdered NaOH (25.3 g, 2.0 equiv.) was added at 5-10 °C. The solution was aged at 15-20 °C for an additional 0.5 h. A second IPC was analyzed, which showed 50% conversion. A final addition of powdered NaOH (25.3 g, 2.0 equiv.) was added at 5-10 °C. The mixture was stirred at 15-20 °C for an additional 0.5 h. Analysis showed complete conversion of starting material 10. The mixture was filtered and the filter cake was washed with acetonitrile (2 x 520 mL, 2 vol). The final solution (approximately 7.5 L, 28.8 vol) was concentrated to 1-2 vol while maintaining the temperature between 15-20 °C. The residue was then treated with acetonitrile (2 L, 7.7 vol) and the water content was checked by KF (KF: 5.7%). The mixture was filtered and the filter cake was washed with ACN (2 x 520 mL, 2 vol). The solution was then concentrated under vacuum at 15-20 °C to 1-2 vol. The water content was again checked by KF (KF: 5.5%). The solution was diluted with acetonitrile (390 mL, 1.5 vol) and added dropwise to MTBE (2.6 L, 10 vol) over 0.5 h while maintaining the temperature between 15-20 °C. The solvent was decanted to leave a viscous oil, which was redissolved in acetonitrile (520 mL, 2 vol) and added to MTBE (2.6 L, 10 vol). This process was repeated four more times. A viscous oil was obtained, which was finally dissolved in acetonitrile (520 mL, 2 vol), dried, and then concentrated under reduced pressure at 15-20 °C. Residual solvent was then removed by evaporation using an oil pump at 15-20 °C. After drying, 335 g of compound 11 was obtained as a yellowish solid (QNMR: 70%, 87% overall yield over two steps). LCMS (ES, m / z): 624.3 [M-TfONa-2Na+3H] +1H-NMR(300MHz,Methanol-d4,ppm):δ7.97(dd,J=7.8,2.1Hz,2H),7.84(t,J=7.7Hz,1H),7.75(t,J=7.8Hz,1H),7.36(dd,J=7.8,1.1Hz,1H),7. 23(d,J=7.7Hz,1H),7.11(d,J=8.5Hz,2H),6.72(d,J=8.5Hz,2H),3.96(s,1H),3.83-3.36(m,18H),3.03-2.62(m,6H),2.55(d,J=14.3Hz,2H).
[0444] Preparation of compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt):
[0445] [ka]
[0446] TCDI (68.7 g, 1.4 equiv.) and acetonitrile (2.6 L, 8 vol.) were placed in a 10 L reaction vessel under nitrogen atmosphere at 15-20 °C. Compound 11 (330 g, Na) in acetonitrile (660 mL, 2 vol.) was added while maintaining the temperature at 15-20 °C. +A solution of 1.0 eq. (salt, QNMR: 70%, 1.0 equiv.) was added dropwise over 30 min. The mixture was aged at 15-20 °C for 0.5 h. Analysis of the mixture (sample preparation: 30 μL solution + 300 μL ACN + 1 drop water) indicated the reaction had reached completion. The water content was checked by KF (KF: 0.19%). The solution was dried and concentrated under reduced pressure at 15-20 °C. The resulting residue was dissolved in acetonitrile (945 mL, 2.9 vol) and the water content was measured by KF (KF: 0.34%). Isopropyl acetate (660 mL, 2 vol.) was added to the solution over 40 min at 15-20 °C. No nucleation was observed and additional isopropyl acetate (6.6 L, 18 vol.) was slowly charged dropwise over 40 min at 15-20 °C, resulting in precipitation of product 12, which was collected by filtration as a yellowish solid. The solid was dissolved in acetonitrile (330 mL, 1 vol) and IPAc (6.6 L, 20 vol) was added dropwise slowly over 40 min at 15-20 °C. The mixture was filtered to give 230 g of product as a yellowish solid (LCAP: 80.99%, QNMR: 59%, 10% IPAc). The wet cake was dried under vacuum at 15-20 °C for 2 h to give 224 g of crude product 12 as a yellowish solid (LCAP: 80.9%, QNMR: 60.4%, ca. 6% IPAc). The crude product 12 was redissolved in acetonitrile (330 mL, 1 vol) and isopropyl acetate (412 mL, 1.25 vol) was added dropwise slowly over 40 min at 15-20 °C. The resulting mixture was filtered to recover 12 (30.5 g, HPLC = 60.9%, Assay: 25.5%). The mother liquor was diluted with isopropyl acetate (6.6 L, 20 volumes) added over 40 min at 15-20 °C. The mixture was filtered and the cake was dried to give 173.5 g of crude product 12 as a yellowish solid (LCAP: 85.4%, QNMR: 66%, 3.9% IPAc, RRT1.19 = 3.9%). 190 g of the crude product 12 was dissolved in 760 mL of acetonitrile:isopropyl acetate (2:1) and the mixture was passed through a silica gel column (380 g, 2x). The silica was flushed with acetonitrile:isopropyl acetate (2:1, 5.7 L) and then with 12 L of acetonitrile (very little product).The product-containing fractions were concentrated to give 118 g of product 12 as a yellowish solid (LCAP: 95%). The silica pad was then rinsed with MeCN / HO (12 L, 10:1). The solvent was removed in vacuo to give an additional 60 g of crude product 12 as a yellowish solid, which was dissolved in acetonitrile (1.5 L), stirred for 30 min, and then filtered. The mother liquor was then concentrated to give 24 g of crude product 12 as a yellowish solid (LCAP = 92%). Crude product 12 (118 g) and crude product 12 (24 g) prepared as above were dissolved in acetonitrile (330 mL, 1 vol) and isopropyl acetate (6.6 L, 20 vol) was added dropwise over 40 min at 15-20 °C. The mixture was then filtered to give 133 g of product 12 as a yellowish solid of suitable purity (LCAP: 95%, QNMR: 60.8%, 7.8% IPAc). Note: Compound 12 required storage at -20°C. LCMS: (ES, m / z): 666.61 [M-TfONa-2Na+3H]. +1 H-NMR: (400MHz, methanol-d4, ppm): δ8.00(ddd,J=13.8,7.7,1.0Hz,2H),7.84(dt,J=20. 4,7.7Hz,2H),7.58-7.49(m,2H),7.40(dd,J=7.6,1.0Hz,1H),7.36-7.28(m,2H),7.28 -7.20(m,1H),4.96(hept,J=6.3Hz,1H),3.96-3.88(m,1H),3.83(d,J=15.1Hz,1H),3. 70-3.52 (m, 11H), 3.55-3.39 (m, 4H), 3.07-2.73 (m, 6H), 2.62 (dt, J=15.1, 3.6Hz, 2H).
[0447] Example 10 TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate
[0448] [ka]
[0449] (In the TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate above, the structure does not show the lysine residue of h11B6 linked to the phenylthiourea moiety.)
[0450] TOPA-[C7]-phenylthiourea modification of mAbs: h11b6 mAb (10.2 mg / mL) was diluted to 1 mg / mL in 10 mM sodium acetate pH 5.2 buffer. Just before conjugation, the pH was adjusted to pH 9 with sodium bicarbonate buffer (VWR 144-55-8). The pH was confirmed with pH paper. A 10-fold molar excess of disodium salt TOPA-[C7]-phenylisothiocyanate sodium salt (50 mM stock dissolved in water) was then added to h11b6 mAb, and the mixture of antibody and TOPA-[C7]-phenylisothiocyanate sodium salt was incubated for approximately 1 hour at room temperature without shaking. The addition of TOPA-[C7]-phenylisothiocyanate sodium salt was monitored by intact mass ESI-TOF LC-MS on an Agilent® G224 instrument until the CAR value was between 1.5 and 2.0. The mixture was immediately quenched to a final concentration of 100 mM by adding 1M Tris, pH 8.5 (Teknova T1085). Excess free chelator was removed by desalting the reaction into 10 mM sodium acetate pH 5.2 using a 7K Zeba® desalting column. Three sample dilutions to 15 mL were performed to confirm the absence of excess chelator, followed by concentration to 1 mL using a 50,000 MWCO Amicon concentrator. The sample was then concentrated to its final concentration for radiolabeling. The final conjugate was confirmed to be monomeric by analytical size exclusion chromatography on a Tosoh TSKgel G3000SWxl 7.8 mm x 30 cm, 5u column, column temperature: room temperature, eluting the column with 0.2 M sodium phosphate, pH 6.8, flow rate: 0.8 mL / min, 18 min run, injection volume: 18 μL.
[0451] Example 11 Ac-225 labeled TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate
[0452] [ka]
[0453] (In the Ac-225 labeled TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate above, the structure does not show the lysine residue of h11B6 linked to the phenylthiourea moiety.)
[0454] (i) Labeling of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 3M NaOAc buffer: To a solution of NaOAc (3M in HO, 60 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 15 μL) and TOPA-[C7]-phenylthiourea-h11B6 (1.13 mg / mL in 10 mM NaOAc pH=5.5, 441 μL, 0.5 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37° C. for 2 hours.
[0455] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was loaded onto iTLC-SG, which was developed with 10 mM EDTA (pH 5-6). The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6-bound Ac-225 remained at the origin and any free Ac-225 migrated with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was bound to Ac-225.
[0456] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 remained at the origin and any free Ac-225 would have migrated with the solvent to the solvent front. The iTLC scan showed that 99.7% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.
[0457] Purification on PD10 column: The PD-10 resin was conditioned with NaOAc buffer by passing 3×5 mL of NaOAc buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) through the column and discarding the washes. The entire labeling reaction mixture was applied to the reservoir of the column and the eluate was collected in pre-numbered plastic tubes. The reaction vial was washed 3×0.2 mL with NaOAc buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5), the washes were pipetted into the reservoir of the PD-10 column and the eluate was collected. Each tube contained approximately 1 mL of eluate. Continuous application of NaOAc buffer (25 mM NaOAc, 0.04% PS-20, pH 5.5) to the reservoir of the PD-10 column was performed until a total elution volume of 10 mL was reached. The radiochemical purity of the collected fractions was checked by iTLC. 10 uL of each collected fraction was spotted onto iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Pure fractions should have no radioactive signal at the solvent front of the iTLC-SG.
[0458] Refined 225 DTPA challenge of Ac-TOPA-[C7]-phenylthiourea-h11B6: 10 μL of fraction #3 collected after the PD-10 column was mixed with 15 μL of 10 mM DTPA solution (pH 6.5) and incubated for 30 min. 10 μL of the mixture was loaded onto iTLC-SG, which was developed with 10 mM EDTA and dried overnight. It was scanned on a Bioscan AR-2000 radio-TLC scanner. No radioactive signal was observed at the solvent front of iTLC-SG, indicating that there was no free Ac-225 in fraction #3.
[0459] Refined 225 HPLC analysis of Ac-TOPA-[C7]-phenylthiourea-h11B6: Fraction #3 collected after the PD-10 column was analyzed by HPLC. HPLC method: Tosoh TSKgel G3000SWxl 7.8mm x 30cm, 5μm column, column temperature: room temperature, the column was eluted with DPBS buffer (x1, calcium and magnesium free), flow rate: 0.7mL / min, 20min run, injection volume: 40μL. After HPLC, fractions were collected at 30s or 1min time intervals. The collected HPLC fractions were left overnight at room temperature. The radioactivity of each of the collected fractions was counted in a gamma counter. HPLC radioactivity traces were constructed from the radioactivity in each HPLC fraction. The HPLC radioactivity traces showed a radioactivity peak corresponding to the TOPA-[C7]-phenylthiourea-h11B6 peak on the HPLC UV trace.
[0460] (ii) Labeling of higher concentrations of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 1.5M NaOAc buffer: To a solution of NaOAc (1.5M in HO with 0.04% PS-20, 63 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 10 μL) and TOPA-[C7]-phenylthiourea-h11B6 (9.36 mg / mL in 10 mM NaOAc pH=5.2, 0.04% PS-20, 36 uL, 337 μg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37°C for 2 hours.
[0461] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was then loaded onto iTLC-SG, which was developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.
[0462] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.
[0463] (iii) Labeling of higher concentrations of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 1M NaOAc buffer: To a solution of NaOAc (1.0M in HO with 0.04% PS-20, 63 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 10 μL) and TOPA-[C7]-phenylthiourea-h11B6 (9.36 mg / mL in 10 mM NaOAc pH=5.2, 0.04% PS-20, 36 uL, 337 μg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37°C for 2 hours.
[0464] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was then loaded onto iTLC-SG, which was developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.
[0465] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.
[0466] Labeling of higher concentrations of TOPA-[C7]-phenylthiourea-h11B6 with Ac-225 in 25 mM NaOAc buffer (containing 0.4% Tween-20, pH 5.5): To a solution of NaOAc (25 mM in HO, pH 5.5, 0.04% PS-20, 10 μL) in a plastic vial, Ac-225 (10 mCi / mL in 0.1 N HCl, 5 μL), TOPA-[C7]-phenylthiourea-h11B6 (10.4 mg / mL in 10 mM NaOAc, pH=5.2, 16 uL, 166 μg), and NaOH (0.1 M, 5 μL) were added sequentially. After mixing, the pH was approximately 6.0 by pH paper. The vial was left at 37° C. for 2 hours.
[0467] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was then loaded onto iTLC-SG, which was developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.9% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.
[0468] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted on iTLC-SG and developed with 10 mM EDTA. The dried iTLC-SG was left at room temperature overnight and then scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.8% of TOPA-[C7]-phenylthiourea-h11B6 was chelated to Ac-225.
[0469] [Table 3]
[0470] Example 12 The following series of experiments was carried out to investigate the effect of the presence of non-radioactive metal impurities associated with the actinium sources of TOPA and DOTA chelating macrocycles. 225 Al, the four most important impurities found in the ORNL source of Ac(NO3)3 3+ , Ca 2+ , Zn 2+ , Mg 2+ was used as a spike standard in the chelation reaction of DOTA and TOPA conjugated to h11b6. The chelation results were monitored by iTLC and then challenged with DTPA.
[0471] Chelation of TOPA-[C7]-phenylthiourea-h11b6 with Ac-225 in the presence of metal impurities (low concentration impurities).
[0472] [ka]
[0473] (In the Ac-225 labeled TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate above, the structure does not show the lysine residue of h11B6 linked to the phenylthiourea moiety.)
[0474] Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 9.76 μg / mCi, 3.83 μg / mCi, 0.61 μg / mCi, and 0.27 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and TOPA-[C7]-phenylthiourea-h11b6 (1.17 mg / mL in 10 mM NaOAc pH=5.5, 143 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37°C for 2 hours.
[0475] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was then loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent front. The iTLC scan showed that 99.5% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 1, shown in Figure 5).
[0476] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before being scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11b6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.4% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 2, shown in FIG. 6).
[0477] Metal addition experiment: Labeling of TOPA-[C7]-phenylthiourea-h11b6 with Ac-225 in the presence of metal impurities (higher concentration of impurity, 5-fold increase compared to lower concentration of impurity).
[0478] [ka]
[0479] Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 45.0 μg / mCi, 17.3 μg / mCi, 3.01 μg / mCi, and 1.15 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and TOPA-[C7]-phenylthiourea-h11b6 (1.17 mg / mL in 10 mM NaOAc pH=5.5, 143 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37°C for 2 hours.
[0480] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was then loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to TOPA-[C7]-phenylthiourea-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent front. The iTLC scan showed that 98.9% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 3, shown in FIG. 7).
[0481] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before being scanned on a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, TOPA-[C7]-phenylthiourea-h11b6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 99.8% of Ac-225 was bound to TOPA-[C7]-phenylthiourea-h11b6 (scan 4, shown in FIG. 8).
[0482] Chelation of DOTA-h11b6 with Ac-225 in the presence of metal impurities (low concentration impurities).
[0483] [ka]
[0484] Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 9.76 μg / mCi, 3.83 μg / mCi, 0.61 μg / mCi, and 0.27 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and DOTA-h11b6 (10 mg / mL in 25 mM NaOAc pH=5.5, 16.7 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37° C. for 2 hours.
[0485] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was then loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to DOTA-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent front. The iTLC scan showed that 43.6% of Ac-225 was chelated to DOTA-h11b6 (scan 5, shown in FIG. 9).
[0486] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before being scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, DOTA-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 18.1% of Ac-225 was chelated to DOTA-h11b6 (scan 6, shown in FIG. 10).
[0487] Metal addition experiment: Labeling of DOTA-h11b6 with Ac-225 in the presence of metal impurities (higher concentration of impurity, 5-fold increase compared to lower concentration of impurity).
[0488] [ka]
[0489] Ac-225 was dissolved in 0.1M HCl and mixed with AlCl3, CaCl2, ZnCl2, and MgCl2 to form a 5 mCi / mL solution. The concentrations of aluminum, calcium, zinc, and magnesium are 45.0 μg / mCi, 17.3 μg / mCi, 3.01 μg / mCi, and 1.15 μg / mCi, respectively. To a solution of NaOAc (3M in H2O, 20 μL) in a plastic vial, Ac-225 (5 mCi / mL in 0.1N HCl, 10 μL, with added metal impurities) and DOTA-h11b6 (10 mg / mL in 25 mM NaOAc pH=5.5, 16.7 μL, 0.167 mg) were added sequentially. After mixing, the pH was approximately 6.5 by pH paper. The vial was left at 37°C for 2 hours.
[0490] iTLC of the labeling reaction mixture: 0.5 μL of the labeling reaction mixture was then loaded onto iTLC-SG and developed with 10 mM EDTA solution. The iTLC-SG was dried overnight at room temperature and then scanned on a Bioscan AR-2000 radioactive TLC scanner. Under the elution conditions described herein, Ac-225 bound to DOTA-h11b6 Ac-225 will remain at the origin (baseline) of the TLC, and any free Ac-225 will migrate with the solvent to the solvent front. The iTLC scan showed that 52.7% of Ac-225 was chelated to DOTA-h11b6 (scan 7, shown in FIG. 11).
[0491] DTPA challenge of labeling reaction mixture: Further, 0.5 μL of the labeling reaction mixture was mixed with 10 mM DTPA (pH=6.5, 15 μL) at 37° C. After 30 min, 10 μL of the mixture was spotted onto iTLC-SG and developed with 10 mM EDTA eluent. The iTLC-SG was air-dried and left at room temperature overnight before being scanned with a Bioscan AR-2000 radio-TLC scanner. Under the elution conditions described herein, DOTA-h11B6 chelated Ac-225 would remain at the origin and any free Ac-225 would migrate with the solvent to the solvent front. The iTLC scan showed that 14.0% of Ac-225 was chelated to DOTA-h11b6 (scan 8, shown in FIG. 12).
[0492] The foregoing specification, together with examples given for purposes of illustration, teaches the principles of the invention, but it will be understood that the practice of the invention encompasses all ordinary modifications, adaptations and / or alterations that come within the scope of the following claims and equivalents thereof.
[0493] Throughout this application, various publications are cited. The disclosures of these publications are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Claims
1. Compound 14 (6-((16-((6-carboxypyridin-2-yl)(4-isothiocyanatophenyl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid), 【Chemistry 1】 or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of: 【Chemistry 2】 reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof at a temperature ranging from ambient temperature to −78° C. to obtain compound 2; 【Chemistry 3】 reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 3; 【Chemistry 4】 reacting 3 with 2 in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate); 【Chemistry 5】 reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 in an organic solvent or mixture thereof under reducing conditions at a temperature ranging from about ambient temperature to about −78° C. to give compound 7; 【Chemistry 6】 reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate); 【Chemistry 7】 reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 9; 【Chemistry 8】 reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10; 【Chemistry 9】 reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain 13, which is reacted with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14.
2. Compound 14, 【Chemistry 10】 or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of: 【Chemistry 11】 reacting 7,16-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (1) with a reducing agent in an organic solvent or mixture thereof at a temperature ranging from ambient temperature to −78° C. to obtain compound 2; 【Chemistry 12】 reacting methyl-6-(hydroxymethyl)picolinate with thionyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 3; 【Chemistry 13】 reacting 3 with 2 in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 4 (6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate); 【Chemistry 14】 reacting methyl-6-formylpicolinate 5 with (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid 6 in an organic solvent or mixture thereof under reducing conditions at a temperature ranging from about ambient temperature to about −78° C. to give compound 7; 【Chemistry 15】 reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)(hydroxy)methyl)picolinate 7 with methanesulfonyl chloride in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 8 (methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate); 【Chemistry 16】 reacting methyl 6-((4-((tert-butoxycarbonyl)amino)phenyl)-((methylsulfonyl)oxy)methyl)picolinate 8 with 6-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate 4 in an organic solvent or a mixture thereof with sodium carbonate at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 9; 【Chemistry 17】 reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C., to which is added a solution of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent to obtain compound 10; 【Chemistry 18】 reacting compound 10 in an organic solvent or mixture thereof under basic conditions at a temperature ranging from about ambient temperature to about −78° C. to obtain 13, which is reacted with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 14.
3. compound 10, 【Chemistry 19】 or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of: 【Chemistry 20】 1. A process comprising reacting compound 9 with N,O-bis(trimethylsilyl)acetamide (BSA) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. and stirring for 5 to 60 minutes, and reacting the same with trimethylsilyl trifluoromethanesulfonate (TMSOTf) in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 10.
4. Compound 12 (TOPA-[C7]-phenylisothiocyanate sodium salt), 【Chemistry 21】 or a pharma- ceutically acceptable salt or solvate thereof, comprising the steps of: 【Chemical 22】 reacting compound 10 with sodium hydroxide in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 11; 【Chemistry 23】 reacting compound 11 with thiocarbonyldiimidazole in an organic solvent or mixture thereof at a temperature ranging from about ambient temperature to about −78° C. to obtain compound 12.
5. 1. A process for preparing a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate, comprising: 【Chemistry 24】 reacting about a 10-fold excess of compound 12 with h11b6 mAb in 10 mM sodium acetate, pH about 5.2 buffer adjusted to a pH of about 9 with sodium bicarbonate buffer, and incubating at room temperature without shaking for about 1 hour; quenching by adding 1 M Tris, pH about 8.5, to a final concentration of about 100 mM; removing excess free chelating agent by desalting the reaction into 10 mM sodium acetate, pH about 5.2; removing the excess chelating agent to obtain a TOPA-[C7]-phenylthiourea-h11B6 antibody conjugate.
6. Compound of formula (12) (TOPA-[C7]-phenylisothiocyanate sodium salt) 【Chemistry 25】
7. Compound of formula (14) 【Chemistry 26】 or a pharma- ceutically acceptable salt or solvate thereof.
8. Compound of formula (11) 【Chemistry 27】
